Anti-CCR8 antibody and antibody-drug conjugate thereof

Abstract

Provided is an antibody-drug conjugate represented by formula (1), or a pharmaceutically acceptable salt thereof. [wherein mAb represents an antibody that binds to CCR8, or a fragment thereof; n represents an integer from 1 to 8; L represents a group represented by formula (L-1), (L-2), (L-3) or (L-4); and Z represents a group represented by formula (Z-1), (Z-2) or (Z-3).]

Description

Anti-CCR8 antibody and its drug conjugate

[0001] This disclosure relates to an antibody that specifically binds to CCR8 and a drug conjugate thereof.

[0002] Regulatory T cells (Treg) are a subset of CD4+CD25+ T cells, using the FOXP3 gene as their master gene (Non-Patent Literature 1). Treg cells are specialized in immunosuppressive function and are thought to suppress excessive immune responses such as autoimmune diseases and inflammation, thereby maintaining immune homeostasis. There are reports that autoimmune diseases occur due to Treg cell deficiency or dysfunction (Non-Patent Literature 2). Tumor-infiltrating Treg cells suppress the function of effector T cells and are an important factor in escaping the anti-tumor immune response. In some cancer types, the presence of tumor-infiltrating Treg cells has been reported to be associated with poor prognosis after treatment (Non-Patent Literature 3). Temporary removal of Treg cells leads to strong anti-tumor immunity and tumor regression, enhancing the effectiveness of cancer vaccines (Non-Patent Literature 4). Removing or inhibiting the function of Treg cells infiltrating tumors improves the tumor microenvironment, enhances the anti-tumor immune response, and leads to the development of new cancer immunotherapies. To date, antibodies targeting several targets (such as CD25 and CCR4) have been reported with the aim of eliminating Treg cells via the antibody-dependent cell-mediated cytotoxicity (ADCC) mechanism (Non-patent documents 5 and 6).

[0003] CCR8 has been identified as one of the G protein-coupled chemokine receptors, and CCL1 is known as its endogenous ligand. CCR8 has been reported to be specifically highly expressed in Treg cells that infiltrate tumors of several cancer types, and these Treg cells strongly suppress tumor immunity (Non-Patent Documents 3, 7). Several groups have reported that antibodies targeting CCR8 show antitumor effects in mouse models (Patent Documents 1-12, 18-33).

[0004] An antibody-drug conjugate is a complex formed by directly linking an antibody and a drug, or via an appropriate linker. Antibody-drug conjugates have the characteristic of suppressing systemic exposure to the drug and enhancing its efficacy on target cells by delivering the drug to the target cell via an antibody that binds to an antigen expressed on the target cell.

[0005] The drugs contained in antibody-drug conjugates approved to date target DNA, topoisomerase I, or tubulin. Hemiastarin, a tripeptide isolated from sponges, is known as a drug that targets tubulin and is involved in microtubule depolymerization and mitotic arrest in cells (Non-Patent Literature 8). Several groups have performed structural modifications on hemiastarin derivatives, and hemiastarin derivatives with potent cytotoxicity have been found for the treatment of diseases such as cancer (Non-Patent Literature 9). However, these hemiastarin derivatives themselves are not target-specific and are delivered systemically, exhibiting cytotoxicity to normal cells and causing side effects, as has been reported (Non-Patent Literature 10).

[0006] Several groups have reported hemiastarin derivatives and their antibody-drug conjugates (Patent Documents 13-17). These are conjugates in which a hemiastarin derivative having a maleimide group is combined with a cysteine ​​residue such as an antibody to form a thiosuccinimide, and it has been reported that this thiosuccinimide moiety undergoes a reversible reaction of dissociation and binding in vivo (Non-Patent Documents 11, 12).

[0007] International Publication No. 2018 / 181425, International Publication No. 2019 / 157098, Patent No. 6894086, International Publication No. 2021 / 142002, International Publication No. 2021 / 163064, International Publication No. 2021 / 178749, International Publication No. 2021 / 194942, International Publication No. 2021 / 152186, International Publication No. 2022 / 003156, International Publication No. 2022 / 042690, International Publication No. 2022 / 081718, International Publication No. 2022 / 078277, International Publication No. 2015 / 095952, International Publication No. 2015 / 095953, International Publication No. 2014 / 057436, International Publication No. 2019 / 031614, International Publication No. 2006 / 0 International Publication No. 63135, International Publication No. 2022 / 241034, International Publication No. 2022 / 256563, International Publication No. 2022 / 268192, International Publication No. 2023 / 288241, International Publication No. 2023 / 010054, International Publication No. 2023 / 116880, International Publication No. 2023 / 137466, International Publication No. 2023 / 1937 International Publication No. 32, International Publication No. 2023 / 208182, International Publication No. 2024 / 027823, International Publication No. 2024 / 040216, International Publication No. 2024 / 062076, International Publication No. 2024 / 094003, International Publication No. 2024 / 109657, International Publication No. 2024 / 120418, International Publication No. 2024 / 227083

[0008] Li, C. et al. , Molecular Cancer, 2020, 19, 116. Sakaguchi, S. et al. , Immunol Rev, 2006, 212, 8-27. Plitas, G. et al. , Immunity, 2016, 15, 1122-1134. Fisher, S. et al. , Immun. Inflamm. Dis. , 2017, 5, 16-28. Arce Vargas, F. et al. , Immunity, 2017, 46, 577-586. Kurose, K. et al. , Clin. Cancer Res. , 2015, 21, 4327-4336. Yi, G. et al. , Sci. Bull. , 2018, 63, 972-981. Talpir, R. et al. , Tetrahedron Lett. , 1994, 35, 4453-4456. Galina Kuznetsov,G. et al. , Mol. Cancer Ther. , 2009, 8, 2852-60. Rocha-Lima, C. M. et. al. , Cancer, 2012, 118, 4262-4270. Alley, S. C. etc. al. , Bioconjugate Chem. , 2008, 19, 759-765. Baldwin, A. D. etc. al. , Bioconjugate Chem. , 2011, 22, 1946-1953.

[0009] In antibody-based therapy targeting Treg cells, even if the antibody recognizes the antigen and exhibits ADCC activity, the antitumor effect may not be sufficient. The objective of this disclosure is to provide an antibody-drug conjugate that exhibits an antitumor effect by eliminating Treg cells independently of the immune state, including ADCC activity. "Exhibiting an antitumor effect by eliminating Treg cells independently of the immune state, including ADCC activity" means that the antitumor effect is exhibited by eliminating Treg cells through a mechanism other than one involving the immune state, including ADCC activity.

[0010] This disclosure provides an antibody-drug conjugate capable of eliminating tumor-infiltrating CCR8-positive Treg cells by forming a stable drug conjugate with an anti-CCR8 antibody and an ADC synthesis intermediate having the anti-CCR8 antibody and a hemiastarin derivative. Specifically, the antibody-drug conjugate of this disclosure binds to the antigen CCR8 expressed on the surface of target cells, tumor-infiltrating Treg cells, then internalizes within the cell, and further releases the drug portion, the hemiastarin derivative, through metabolism, exhibiting cytotoxicity. Thus, we have discovered an antibody-drug conjugate that serves as a highly effective antitumor agent capable of eliminating tumor-infiltrating CCR8-positive Treg cells, thus completing the invention of this disclosure.

[0011] In other words, this disclosure relates to the following:

[0012] [Item 1] An antibody-drug conjugate represented by formula (1) or a pharmaceutically acceptable salt thereof. [In the formula, mAb represents an antibody that binds to CCR8, or a fragment thereof; n represents an integer from 1 to 8; and L represents a group represented by the following formulas (L-1), (L-2), (L-3), or (L-4).] (In the formula, p represents an integer from 1 to 5, AB represents a peptide residue consisting of 1 to 4 amino acids selected from the group consisting of glycine (Gly), phenylalanine (Phe), valine (Val), citrulline (Cit), asparagine (Asn), alanine (Ala), glutamic acid (Glu), and aspartic acid (Asp), the * part forms a bond with the nitrogen atom of the succinimide group, and the wavy part forms a bond with Z) Z represents the group represented by formula (Z-1), formula (Z-2), or formula (Z-3): (In the formula, m represents an integer from 0 to 4, and Q represents a 6-10 member aromatic hydrocarbon ring group or a 5-10 member aromatic heterocyclic group, and the aromatic hydrocarbon ring group and the aromatic heterocyclic group may be substituted with halogen atoms, cyano groups, amino groups, or 1 to 3 fluorine atoms.) １－３ Alkyl groups, hydroxyl groups and C １－４ R may be substituted with one to five identical or different substituents selected from the group consisting of alkoxy groups. １ａ and R １ｂ Each of them is independently a hydrogen atom, C１－６ An alkyl group or a C ３－８ represents a saturated hydrocarbon ring group, and the alkyl group and the saturated hydrocarbon ring group may be substituted with the same or different 1 to 5 substituents selected from the group consisting of a halogen atom, a hydroxy group, a C １－３ alkyl group and a C １－４ alkoxy group. R １ｃ represents a C １－６ alkylene group, and the C １－６ alkylene group may be substituted with the same or different 1 to 5 substituents selected from the group consisting of a halogen atom, an amino group, a hydroxy group and a C １－４ alkoxy group. R ２ represents a hydrogen atom, a halogen atom, a hydroxy group, a C １－３ alkyl group, a C １－４ alkoxy group or a C １－４ thioalkoxy group. AA represents a glutamic acid residue (Glu), an aspartic acid residue (Asp), a lysine residue (Lys), a serine residue (Ser), an ornithine residue (Orn), or a group derived from a compound represented by formula (AA-1) or formula (AA-2). (In the formula, R １ｄ and R １ｅ each independently represent a hydrogen atom, a C １－６ alkyl group or a polyethylene glycol group, and the C １－６ alkyl group may be substituted with the same or different 1 to 5 substituents selected from the group consisting of a halogen atom, a hydroxy group and a C １－４ alkoxy group. p １ represents an integer of 1 to 5, and p ２ represents an integer of 1 to 3). When there are a plurality of AAs, each AA may be the same as or different from each other, and the AAs are linearly or branchedly bonded via an amide bond. (AA) ｍThe nitrogen atom at the N-terminus or side chain forms an amide bond with the carbonyl group (#), provided that when Z is the group represented by formula (Z-1) and L is the group represented by formula (L-2), formula (L-3), or formula (L-4), m is an integer from 1 to 4, and at least one AA is derived from an ornithine residue or a compound represented by formula (AA-1), and when Z is the group represented by formula (Z-2) or formula (Z-3) and m is 0, (AA) ｍ (This is a hydroxyl group.)

[0013] [Item 2] The antibody-drug conjugate described in Item 1 or a pharmaceutically acceptable salt thereof, wherein AB is a peptide residue composed of 1 to 4 amino acids selected from the group consisting of glycine (Gly), phenylalanine (Phe), valine (Val), citrulline (Cit), asparagine (Asn), alanine (Ala), and glutamic acid (Glu).

[0014] [Item 3] The antibody-drug conjugate according to item 1 or item 2, or a pharmaceutically acceptable salt thereof, wherein AB is a peptide residue selected from the group consisting of -Val-Cit-, -Gly-Gly-Phe-Gly-, -Ala-Ala-, -Glu-Ala-Ala-, -Gly-Asn-, -Asn-, and -Glu-Asn-.

[0015] [Section 4] R １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－４ An antibody-drug conjugate according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, which may be substituted with one to three identical or different substituents selected from the group consisting of alkoxy groups.

[0016] [Item 5] An antibody-drug conjugate according to any one of items 1 to 4, or a pharmaceutically acceptable salt thereof, wherein p is an integer between 2 and 5.

[0017] [Item 6] An antibody-drug conjugate according to any one of items 1 to 5, or a pharmaceutically acceptable salt thereof, wherein m is an integer from 0 to 2.

[0018] [Item 7] AA is a group derived from D-Glu, D-Orn, D-Lys, or a compound represented by formula (AA-1) or formula (AA-2), R １ｄ and R １ｅ Each of them is independently a hydrogen atom, C １－６ The C is an alkyl group or a polyethylene glycol group. １－６ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－４ An antibody-drug conjugate according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, which may be substituted with one to three identical or different substituents selected from the group consisting of alkoxy groups.

[0019] [Section 8] p １ is 3 or 4, p ２ An antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 7, wherein is 1 or 2.

[0020] [Item 9] Q is a phenyl group, a 1-naphthyl group, a 2-naphthyl group, a pyridyl group, a pyridazyl group, a pyrazyl group, a thienyl group, a pyrrole group, a thiazole group, an isothiazole group, a pyrazole group, a furanyl group, an oxazole group, an isoxazole group, a quinolinyl group, an isoquinolinyl group, a naphthilidinyl group, a quinazolinyl group, a benzofuranyl group, a benzothienyl group, an indolyl group, a 1H-indazolyl group, or a 2H-indazolyl group. The phenyl group, the 1-naphthyl group, the 2-naphthyl group, the pyridyl group, the pyridazyl group, the pyrazyl group, the thienyl group, the pyrrole group, the thiazole group, the isothiazole group, the pyrazole group, the furanyl group, the oxazole group, the isoxazole group, the quinolinyl group, the isoquinolinyl group, the naphthylidinyl group, the quinazolinyl group, the benzofuranyl group, the benzothienyl group, the indolyl group, the 1H-indazolyl group and the 2H-indazolyl group may be substituted with halogen atoms, cyano groups, amino groups, or 1 to 3 fluorine atoms. １－３ Alkyl groups, hydroxyl groups and C １－４An antibody-drug conjugate according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, which may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups.

[0021] [Item 10] Q is a phenyl group, a thienyl group, a pyridyl group, or an indolyl group, and the phenyl group, the thienyl group, the pyridyl group, and the indolyl group may be substituted with a halogen atom, a cyano group, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl groups, hydroxyl groups and C １－４ An antibody-drug conjugate according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, which may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups.

[0022] [Item 11] An antibody-drug conjugate according to any one of items 1 to 10, or a pharmaceutically acceptable salt thereof, wherein m is 0 or 1.

[0023] [Item 12] An antibody-drug conjugate according to any one of items 1 to 11, or a pharmaceutically acceptable salt thereof, wherein Z is a group represented by formula (Z-1).

[0024] [Item 13] An antibody-drug conjugate according to any one of items 1 to 11, or a pharmaceutically acceptable salt thereof, wherein Z is a group represented by formula (Z-2).

[0025] [Item 14] An antibody-drug conjugate according to any one of items 1 to 11, or a pharmaceutically acceptable salt thereof, wherein Z is a group represented by formula (Z-3).

[0026] [Item 15] L is a group represented by formula (L-1), formula (L-2), formula (L-3), or formula (L-4), p is an integer from 2 to 5, AB is a peptide residue consisting of 1 to 4 amino acids selected from the group consisting of glycine (Gly), phenylalanine (Phe), valine (Val), citrulline (Cit), asparagine (Asn), alanine (Ala), glutamic acid (Glu), and aspartic acid (Asp), Z is a group represented by formula (Z-1), m is 1, Q is a phenyl group, a thienyl group, a pyridyl group, or an indolyl group, and the phenyl group, the thienyl group, the pyridyl group, and the indolyl group may be substituted with a halogen atom, a cyano group, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl groups, hydroxyl groups and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups, and AA is a group derived from D-Glu, D-Orn, D-Lys, or a compound represented by formula (AA-1) or formula (AA-2), １ｄ and R １ｅ However, each is independent of the hydrogen atom, C １－３ The C is an alkyl group or a polyethylene glycol group. １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－４ The substituents may be the same or different substituents selected from the group consisting of alkoxy groups, p １ is 3 or 4, p ２ An antibody-drug conjugate or a pharmaceutically acceptable salt thereof as described in item 1, wherein the ratio is 1 or 2.

[0027] [Item 16] L is a group represented by formula (L-1), formula (L-2), or formula (L-3), p is an integer from 2 to 5, AB is a peptide residue consisting of 1 to 4 amino acids selected from the group consisting of glycine (Gly), phenylalanine (Phe), valine (Val), citrulline (Cit), asparagine (Asn), alanine (Ala), glutamic acid (Glu), and aspartic acid (Asp), Z is a group represented by formula (Z-1), m is 1, and Q is a phenyl group or an indolyl group, the phenyl group and the indolyl group may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups, and AA is a group derived from D-Glu, D-Orn, D-Lys, or a compound represented by formula (AA-1) or formula (AA-2), １ｄ and R １ｅ However, each is independent of the hydrogen atom, C １－３ It is an alkyl group or polyethylene glycol group, p １ is 3 or 4, p ２ An antibody-drug conjugate or a pharmaceutically acceptable salt thereof as described in item 1, wherein the ratio is 1 or 2.

[0028] [Item 17] C where L is a group represented by formula (L-1) or (L-2), p is 2, Z is a group represented by formula (Z-1), m is 1, and Q is a phenyl group or an indolyl group, and the phenyl group and the indolyl group may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４R, which may be substituted with one or two identical or different substituents selected from the group consisting of an alkoxy group １ａ and R １ｂ are each independently a hydrogen atom or a C １－３ alkyl group, and the C １－３ alkyl group may be substituted with one or two identical or different substituents selected from the group consisting of a halogen atom, a hydroxy group, and a C １－３ alkoxy group; AA is a group derived from D-Glu or a compound represented by formula (AA-1) or formula (AA-2); R １ｄ and R １ｅ are each independently a hydrogen atom, a C １－３ alkyl group or a polyethylene glycol group; p １ is 3 or 4; p ２ is 1 or 2, the antibody-drug conjugate according to item 1 or a pharmaceutically acceptable salt thereof.

[0029] [Item 18] L is a group represented by formula (L-1) or (L-2); p is 2; Z is a group represented by formula (Z-1); m is 1; Q is a phenyl group or an indolyl group, and the phenyl group and the indolyl group may be substituted with one substituent selected from the group consisting of a halogen atom, an amino group, a C １－３ alkyl group optionally substituted with 1 to 3 fluorine atoms, and a C １－４ alkoxy group; R １ａ and R １ｂ are each independently a hydrogen atom or a C １－３ alkyl group, and the C １－３ alkyl group may be substituted with one substituent selected from the group consisting of a halogen atom, a hydroxy group, and a C １－３ alkoxy group; AA is a group derived from D-Glu or a compound represented by formula (AA-1); R １ｄ and R １ｅ are each independently a hydrogen atom, a C １－３ alkyl group or a polyethylene glycol group; p １The antibody-drug conjugate according to item 1 or a pharmaceutically acceptable salt thereof, wherein [the relevant parameter] is 3 or 4.

[0030] [Item 19] L is a group represented by formula (L-1), p is 2, Z is a group represented by formula (Z-1), m is 1, Q is a phenyl group or an indolyl group, and the phenyl group and the indolyl group may be substituted with a halogen atom, an amino group, a C alkyl group substituted with 1 to 3 fluorine atoms, and a C １－３ alkyl group and C １－４ alkoxy group, and may be substituted with one substituent selected from the group consisting of, R １ａ and R １ｂ are each independently a hydrogen atom or a C １－３ alkyl group, and the C １－３ alkyl group may be substituted with one substituent selected from the group consisting of a halogen atom, a hydroxy group, and a C １－３ alkoxy group, and AA is D-Glu. The antibody-drug conjugate according to item 1 or a pharmaceutically acceptable salt thereof.

[0031] [Item 20] L is a group represented by formula (L-1), p is 2, Z is a group represented by formula (Z-1), m is 1, Q is a phenyl group, and the phenyl group may be substituted with a halogen atom, an amino group, a C alkyl group substituted with 1 to 3 fluorine atoms, and a C １－３ alkyl group and C １－４ alkoxy group, and may be substituted with one substituent selected from the group consisting of, R １ａ and R １ｂ are each independently a hydrogen atom or a C １－３ alkyl group, and the C １－３ alkyl group may be substituted with one substituent selected from the group consisting of a halogen atom, a hydroxy group, and a C １－３ alkoxy group, and AA is D-Glu. The antibody-drug conjugate according to item 1 or a pharmaceutically acceptable salt thereof.

[0032] [Item 21] L is a group represented by formula (L-2), formula (L-3), or formula (L-4), p is an integer from 2 to 5, AB is a peptide residue consisting of 1 to 4 amino acids selected from the group consisting of glycine (Gly), phenylalanine (Phe), valine (Val), citrulline (Cit), asparagine (Asn), alanine (Ala), glutamic acid (Glu), and aspartic acid (Asp), Z is a group represented by formula (Z-2), m is 0 or 1, except when m is 0, (AA) ｍ C is a hydroxyl group, and Q is a phenyl group, a thienyl group, a pyridyl group, or an indolyl group, and the phenyl group, the thienyl group, the pyridyl group, and the indolyl group may be substituted with a halogen atom, a cyano group, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl groups, hydroxyl groups and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. ２ However, hydrogen atoms, halogen atoms, hydroxyl groups, C １－３ Alkyl alkyl group, C １－４ Alkoxy group or C １－４ It is a thioalkoxy group, where AA is a group derived from D-Glu, D-Orn, D-Lys, or a compound represented by formula (AA-1) or formula (AA-2), and R １ｄ and R １ｅ However, each is independent of the hydrogen atom, C １－３ The C is an alkyl group or a polyethylene glycol group. １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－４ The substituents may be the same or different substituents selected from the group consisting of alkoxy groups, p １ is 3 or 4, p２ An antibody-drug conjugate or a pharmaceutically acceptable salt thereof as described in item 1, wherein the ratio is 1 or 2.

[0033] [Item 22] L is a group represented by formula (L-3) or formula (L-4), p is an integer from 2 to 5, AB is a peptide residue selected from the group consisting of -Val-Cit-, -Gly-Gly-Phe-Gly-, -Ala-Ala-, -Glu-Ala-Ala-, -Gly-Asn-, -Asn-, and -Glu-Asn-, Z is a group represented by formula (Z-2), m is 0 or 1, except when m is 0, (AA) ｍ C is a hydroxyl group, and Q is a phenyl group or an indolyl group, and the phenyl group and the indolyl group may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. ２ However, hydrogen atoms, halogen atoms, C １－３ The group is an alkyl group, a methoxy group, a methylthio group, an ethylthio group, or a tert-butylthio group, and AA is a group derived from D-Glu or a compound represented by formula (AA-2), R １ｄ and R １ｅ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, p ２ An antibody-drug conjugate or a pharmaceutically acceptable salt thereof as described in item 1, wherein the ratio is 1 or 2.

[0034] [Item 23] L is a group represented by formula (L-1), formula (L-2), formula (L-3), or formula (L-4), p is an integer from 2 to 5, AB is a peptide residue consisting of 1 to 4 amino acids selected from the group consisting of glycine (Gly), phenylalanine (Phe), valine (Val), citrulline (Cit), asparagine (Asn), alanine (Ala), glutamic acid (Glu), and aspartic acid (Asp), Z is a group represented by formula (Z-3), m is 0 or 1, except when m is 0, (AA) ｍ C is a hydroxyl group, and Q is a phenyl group, a thienyl group, a pyridyl group, or an indolyl group, and the phenyl group, the thienyl group, the pyridyl group, and the indolyl group may be substituted with a halogen atom, a cyano group, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl groups, hydroxyl groups and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ａ However, hydrogen atoms or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ｃ However, C １－６ It is an alkylene group, and the C １－６ Alkylene groups consist of a halogen atom, an amino group, a hydroxyl group, and C １－４ R may be substituted with one to five identical or different substituents selected from the group consisting of alkoxy groups. ２ However, hydrogen atoms, halogen atoms, hydroxyl groups, C １－３ Alkyl alkyl group, C １－４ Alkoxy group or C １－４ It is a thioalkoxy group, where AA is a group derived from D-Glu, D-Orn, D-Lys, or a compound represented by formula (AA-1) or formula (AA-2), and R １ｄ and R １ｅ However, each is independent of the hydrogen atom, C １－３The C is an alkyl group or a polyethylene glycol group. １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－４ The substituents may be the same or different substituents selected from the group consisting of alkoxy groups, p １ is 3 or 4, p ２ An antibody-drug conjugate or a pharmaceutically acceptable salt thereof as described in item 1, wherein the ratio is 1 or 2.

[0035] [Item 24] L is a group represented by formula (L-3) or formula (L-4), p is an integer from 2 to 5, AB is a peptide residue selected from the group consisting of -Val-Cit-, -Gly-Gly-Phe-Gly-, -Ala-Ala-, -Glu-Ala-Ala-, -Gly-Asn-, -Asn- and -Glu-Asn-, Z is a group represented by formula (Z-3), m is 0 or 1, except when m is 0, (AA) ｍ C is a hydroxyl group, and Q is a phenyl group or an indolyl group, and the phenyl group and the indolyl group may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ａ However, hydrogen atoms or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ｃ However, C １－３ It is an alkylene group, and the C １－３ Alkylene groups consist of a halogen atom, an amino group, a hydroxyl group, and C １－４ R may be substituted with one to three identical or different substituents selected from the group consisting of alkoxy groups. ２ However, hydrogen atoms, halogen atoms, C １－３The group is an alkyl group, a methoxy group, a methylthio group, an ethylthio group, or a tert-butylthio group, and AA is a group derived from D-Glu or a compound represented by formula (AA-2), R １ｄ and R １ｅ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, p ２ An antibody-drug conjugate or a pharmaceutically acceptable salt thereof as described in item 1, wherein the ratio is 1 or 2.

[0036] [Item 25] The antibody-drug conjugate described in Item 1, or a pharmaceutically acceptable salt thereof, represented by any of the following formulas. [In the formula, n represents an integer between 1 and 8.]

[0037] [Item 26] The antibody has a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, and the heavy chain variable region and the light chain variable region consist of: (1) CDR-H1, which consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 111, and an amino acid sequence in which one or two amino acids are deleted, substituted, inserted and / or added in the amino acid sequence of SEQ ID NO: 27, SEQ ID NO: 28, or SEQ ID NO: 111; (2) CDR-H2, which consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, and an amino acid sequence in which one or two amino acids are deleted, substituted, inserted and / or added in the amino acid sequence of SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, or SEQ ID NO: 37. (3) CDR-H3 consisting of an amino acid sequence selected from the group consisting of amino acid sequences in which one or two amino acids are deleted, substituted, inserted and / or added in the amino acid sequences of SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 112, or SEQ ID NO: 113, (4) CDR-L1 consisting of an amino acid sequence selected from the group consisting of amino acid sequences in which one or two amino acids are deleted, substituted, inserted and / or added in the amino acid sequences of SEQ ID NO: 43, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, and SEQ ID NO: 43, SEQ ID NO: 55, SEQ ID NO: 56, or SEQ ID NO: 57, (5) CDR-L2 consisting of an amino acid sequence selected from the group consisting of amino acid sequences in which one or two amino acids are deleted, substituted, inserted and / or added in the amino acid sequence of SEQ ID NO: 44, and SEQ ID NO: 44, and (6) An antibody-drug conjugate according to any one of claims 1 to 25 or a pharmaceutically acceptable salt thereof, comprising a complementarity-determining region consisting of CDR-L3, which is an amino acid sequence selected from the group consisting of SEQ ID NO: 45, SEQ ID NO: 46, and an amino acid sequence in which one or two amino acids are deleted, substituted, inserted and / or added in the amino acid sequence of SEQ ID NO: 45 or SEQ ID NO: 46.

[0038] [Item 27] ​​The complementarity determining region consists of: (1) CDR-H1 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 27, 28 and 111; (2) CDR-H2 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 29, 30, 31, 32, 33, 34, 35, 36 and 37; (3) CDR-H3 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 38, 39, 40, 41, 42, 112 and 113; (4) (A) SEQ ID NOs: 43; (B) SEQ ID NOs: 55; (C) SEQ ID NOs: 56; (D) SEQ ID NOs: 57; CDR-L1 consists of an amino acid sequence selected from the group consisting of: (E) an amino acid sequence in which the 11th amino acid in the amino acid sequence of SEQ ID NO: 43 is substituted with alanine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, arginine, asparagine, glutamine, threonine, valine, or lysine; (F) an amino acid sequence in which the 11th amino acid in the amino acid sequence of SEQ ID NO: 55 is substituted with alanine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, or lysine; and (G) an amino acid sequence in which the 11th amino acid in the amino acid sequence of SEQ ID NO: 56 or SEQ ID NO: 57 is substituted with leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, arginine, or lysine; (5) CDR-L2 consists of the amino acid sequence of SEQ ID NO: 44; and (6) The antibody-drug conjugate described in item 26 or a pharmaceutically acceptable salt thereof, comprising CDR-L3, which consists of an amino acid sequence selected from the group consisting of SEQ ID NOs. 45 and SEQ ID NOs. 46.

[0039] [Item 27-1] The antibody has a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, and the heavy chain variable region and the light chain variable region consist of: (1) CDR-H1, which consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 27, SEQ ID NO: 28, and an amino acid sequence in which one or two amino acids are deleted, substituted, inserted and / or added in the amino acid sequence of SEQ ID NO: 27 or SEQ ID NO: 28; (2) CDR-H2, which consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, and an amino acid sequence in which one or two amino acids are deleted, substituted, inserted and / or added in the amino acid sequence of SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36 or SEQ ID NO: 37. (3) CDR-H3 consisting of an amino acid sequence selected from the group consisting of amino acid sequences in which one or two amino acids are deleted, substituted, inserted and / or added in the amino acid sequences of SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, and SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, or SEQ ID NO: 42; (4) CDR-L1 consisting of an amino acid sequence selected from the group consisting of amino acid sequences in which one or two amino acids are deleted, substituted, inserted and / or added in the amino acid sequences of SEQ ID NO: 43, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, and SEQ ID NO: 43, SEQ ID NO: 55, SEQ ID NO: 56, or SEQ ID NO: 57; (5) CDR-L2 consisting of an amino acid sequence selected from the group consisting of amino acid sequences in which one or two amino acids are deleted, substituted, inserted and / or added in the amino acid sequence of SEQ ID NO: 44, and SEQ ID NO: 44; (6) An antibody-drug conjugate according to any one of claims 1 to 25 or a pharmaceutically acceptable salt thereof, comprising a complementarity-determining region consisting of CDR-L3, which is an amino acid sequence selected from the group consisting of SEQ ID NO: 45, SEQ ID NO: 46, and an amino acid sequence in which one or two amino acids are deleted, substituted, inserted and / or added in the amino acid sequence of SEQ ID NO: 45 or SEQ ID NO: 46.

[0040] [Item 27-2] The complementarity determining region is an amino acid sequence in which: (1) CDR-H1 consists of an amino acid sequence selected from the group consisting of SEQ ID NOs. 27 and SEQ ID NOs. 28; (2) CDR-H2 consists of an amino acid sequence selected from the group consisting of SEQ ID NOs. 29, SEQ ID NOs. 30, SEQ ID NOs. 31, SEQ ID NOs. 32, SEQ ID NOs. 33, SEQ ID NOs. 34, SEQ ID NOs. 35, SEQ ID NOs. 36 and SEQ ID NOs. 37; (3) CDR-H3 consists of an amino acid sequence selected from the group consisting of SEQ ID NOs. 38, SEQ ID NOs. 39, SEQ ID NOs. 40, SEQ ID NOs. 41 and SEQ ID NOs. 42; (4) an amino acid sequence in which the 11th amino acid in the amino acid sequences of (A) SEQ ID NOs. 43, (B) SEQ ID NOs. 55, (C) SEQ ID NOs. 56, (D) SEQ ID NOs. 57, and (E) SEQ ID NOs. 43 is substituted with alanine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, arginine, or lysine. CDR-L1 consists of an amino acid sequence selected from the group consisting of (F) an amino acid sequence in which the 11th amino acid in the amino acid sequence of SEQ ID NO: 55 is replaced with alanine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, or lysine, and (G) an amino acid sequence in which the 11th amino acid in the amino acid sequence of SEQ ID NO: 56 or SEQ ID NO: 57 is replaced with leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, arginine, or lysine; (5) CDR-L2 consists of the amino acid sequence of SEQ ID NO: 44; and (6) CDR-L3 consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 45 and SEQ ID NO: 46, or a pharmaceutically acceptable salt thereof, as described in item 27-1.

[0041] [Clause 28] The antibody-drug conjugate according to any one of Clauses 26 to 27-2, wherein CDR-H1 comprises the amino acid sequence of SEQ ID NO: 27, or a pharmaceutically acceptable salt thereof.

[0042] [Clause 29] The antibody-drug conjugate according to any one of Clauses 26 to 28 or a pharmaceutically acceptable salt thereof, wherein the CDR-H2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 35, and SEQ ID NO: 37.

[0043] [Clause 30] The antibody-drug conjugate according to any one of Clauses 26 to 29, wherein the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 29 or SEQ ID NO: 32, or a pharmaceutically acceptable salt thereof.

[0044] [Clause 31] The antibody-drug conjugate according to any one of Clauses 26 to 30 or a pharmaceutically acceptable salt thereof, wherein the CDR-H3 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 41, and SEQ ID NO: 42.

[0045] [Clause 32] The antibody-drug conjugate according to any one of Clauses 26 to 31, wherein the CDR-H3 comprises SEQ ID NO: 38 or SEQ ID NO: 42, or a pharmaceutically acceptable salt thereof.

[0046] [Clause 33] The antibody-drug conjugate or pharmaceutically acceptable salt thereof according to any one of Clauses 26 to 32, wherein CDR-L1 comprises: (1) the amino acid sequence of SEQ ID NO: 43, SEQ ID NO: 55, SEQ ID NO: 56, or SEQ ID NO: 57; (2) the amino acid sequence of SEQ ID NO: 43 in which the 11th amino acid is replaced with alanine; (3) the amino acid sequence of SEQ ID NO: 55 in which the 11th amino acid is replaced with alanine; or (4) the amino acid sequence of SEQ ID NO: 56 or SEQ ID NO: 57 in which the 11th amino acid is replaced with arginine.

[0047] [Clause 34] The antibody-drug conjugate according to any one of Clauses 26 to 33, or a pharmaceutically acceptable salt thereof, wherein the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 43, SEQ ID NO: 55, SEQ ID NO: 56, or SEQ ID NO: 57.

[0048] [Item 35] The complementarity determining region is: A) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; B) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 55, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; C) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 56 A) CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; D) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 57, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; E) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 30, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 39, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; F) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 31, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46;G) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 30, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; H) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; I) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 55, J) CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; J) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 56, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; K) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 57, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; L) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46;M) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 28, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 33, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; N) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 34, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; O) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 35, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; P) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 36, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; Q) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 34, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; or R) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 37, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, An antibody-drug conjugate according to item 26, or a pharmaceutically acceptable salt thereof, comprising CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46.

[0049] [Clause 36] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Clause 26, wherein the complementarity-determining region comprises CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45.

[0050] [Clause 37] The antibody-drug conjugate according to Clause 26 or a pharmaceutically acceptable salt thereof, wherein the complementarity-determining region comprises CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 55, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45.

[0051] [Clause 38] The antibody-drug conjugate according to Clause 26 or a pharmaceutically acceptable salt thereof, wherein the complementarity-determining region comprises CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 56, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45.

[0052] [Clause 39] The antibody-drug conjugate according to Clause 26 or a pharmaceutically acceptable salt thereof, wherein the complementarity-determining region comprises CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 57, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45.

[0053] [Clause 40] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Clause 26, wherein the complementarity-determining region comprises CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46.

[0054] [Clause 41] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Clause 26, wherein the complementarity-determining region comprises CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 55, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46.

[0055] [Clause 42] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Clause 26, wherein the complementarity-determining region comprises CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 56, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46.

[0056] [Clause 43] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Clause 26, wherein the complementarity-determining region comprises CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 57, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46.

[0057] [Clause 44] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Clause 26, wherein the antibody is a humanized antibody.

[0058] [Item 45] The light chain variable region is: (1) the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64 or SEQ ID NO: 65; (2) the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53 or SEQ ID NO: 54, in which the 34th amino acid is substituted with alanine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, arginine, asparagine, glutamine, threonine, valine or lysine; (3) the amino acid sequence of SEQ ID NO: 58, SEQ ID NO: 61 or SEQ ID NO: 64, in which the 34th amino acid is substituted with alanine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid or lysine; or (4) The antibody-drug conjugate or pharmaceutically acceptable salt thereof according to item 44, comprising the amino acid sequence of SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 62, or SEQ ID NO: 63, wherein the 34th amino acid is substituted with leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, arginine, or lysine.

[0059] [Item 45-1] The light chain variable region is: (1) the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64 or SEQ ID NO: 65; (2) the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53 or SEQ ID NO: 54, in which the 34th amino acid is substituted with alanine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, arginine or lysine; (3) the amino acid sequence of SEQ ID NO: 58, SEQ ID NO: 61 or SEQ ID NO: 64, in which the 34th amino acid is substituted with alanine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid or lysine; or (4) The antibody-drug conjugate or pharmaceutically acceptable salt thereof according to item 44, comprising the amino acid sequence of SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 62, or SEQ ID NO: 63, wherein the 34th amino acid is substituted with leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, arginine, or lysine.

[0060] [Clause 46] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Claim 44, wherein the heavy chain variable region consists of an amino acid sequence having 95% or more sequence identity with the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 51 or SEQ ID NO: 52, and the light chain variable region consists of an amino acid sequence having 95% or more sequence identity with the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64 or SEQ ID NO: 65.

[0061] [Clause 47] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Claim 44, wherein the heavy chain variable region consists of an amino acid sequence having 96% or more sequence identity with the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 51 or SEQ ID NO: 52, and the light chain variable region consists of an amino acid sequence having 96% or more sequence identity with the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64 or SEQ ID NO: 65.

[0062] [Clause 48] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Claim 44, wherein the heavy chain variable region consists of an amino acid sequence having 97% or more sequence identity with the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 51 or SEQ ID NO: 52, and the light chain variable region consists of an amino acid sequence having 97% or more sequence identity with the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64 or SEQ ID NO: 65.

[0063] [Clause 49] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Claim 44, wherein the heavy chain variable region consists of an amino acid sequence having 98% or more sequence identity with the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 51 or SEQ ID NO: 52, and the light chain variable region consists of an amino acid sequence having 98% or more sequence identity with the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64 or SEQ ID NO: 65.

[0064] [Clause 50] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Claim 44, wherein the heavy chain variable region consists of an amino acid sequence having 99% or more sequence identity with the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 51 or SEQ ID NO: 52, and the light chain variable region consists of an amino acid sequence having 99% or more sequence identity with the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64 or SEQ ID NO: 65.

[0065] [Clause 51] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Clause 44, wherein the heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 51 or SEQ ID NO: 52, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 or SEQ ID NO: 129.

[0066] [Clause 51-1] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Clause 44, wherein the heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 51 or SEQ ID NO: 52, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64 or SEQ ID NO: 65.

[0067] [Clause 52] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Claim 44, wherein the heavy chain variable region consists of an amino acid sequence having 95% or more sequence identity with the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, or SEQ ID NO: 51, and the light chain variable region consists of an amino acid sequence having 95% or more sequence identity with the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, or SEQ ID NO: 65.

[0068] [Clause 53] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Clause 44, wherein the heavy chain variable region consists of an amino acid sequence having 96% or more sequence identity with the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, or SEQ ID NO: 51, and the light chain variable region consists of an amino acid sequence having 96% or more sequence identity with the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, or SEQ ID NO: 65.

[0069] [Clause 54] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Claim 44, wherein the heavy chain variable region consists of an amino acid sequence having 97% or more sequence identity with the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, or SEQ ID NO: 51, and the light chain variable region consists of an amino acid sequence having 97% or more sequence identity with the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, or SEQ ID NO: 65.

[0070] [Clause 55] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Claim 44, wherein the heavy chain variable region consists of an amino acid sequence having 98% or more sequence identity with the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, or SEQ ID NO: 51, and the light chain variable region consists of an amino acid sequence having 98% or more sequence identity with the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, or SEQ ID NO: 65.

[0071] [Clause 56] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Claim 44, wherein the heavy chain variable region consists of an amino acid sequence having 99% or more sequence identity with the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, or SEQ ID NO: 51, and the light chain variable region consists of an amino acid sequence having 99% or more sequence identity with the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, or SEQ ID NO: 65.

[0072] [Clause 57] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Clause 44, wherein the heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, or SEQ ID NO: 51, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, or SEQ ID NO: 65.

[0073] [Clause 58] The antibody-drug conjugate according to Clause 44 or a pharmaceutically acceptable salt thereof, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 47 and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 49.

[0074] [Clause 59] The antibody-drug conjugate according to Clause 44 or a pharmaceutically acceptable salt thereof, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 47 and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 58.

[0075] [Clause 60] The antibody-drug conjugate according to Claim 44 or a pharmaceutically acceptable salt thereof, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 47 and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 59.

[0076] [Clause 61] The antibody-drug conjugate according to Clause 44 or a pharmaceutically acceptable salt thereof, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 47 and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 60.

[0077] [Clause 62] The antibody-drug conjugate according to Clause 44 or a pharmaceutically acceptable salt thereof, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 48, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 50.

[0078] [Clause 63] The antibody-drug conjugate according to Clause 44 or a pharmaceutically acceptable salt thereof, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 48 and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 61.

[0079] [Clause 64] The antibody-drug conjugate according to Clause 44 or a pharmaceutically acceptable salt thereof, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 48 and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 62.

[0080] [Clause 65] The antibody-drug conjugate according to Clause 44 or a pharmaceutically acceptable salt thereof, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 48 and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 63.

[0081] [Clause 66] The antibody-drug conjugate according to Clause 44 or a pharmaceutically acceptable salt thereof, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 51 and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 53.

[0082] [Clause 67] The antibody-drug conjugate according to Clause 44 or a pharmaceutically acceptable salt thereof, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 51 and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 64.

[0083] [Clause 68] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Clause 26, wherein the heavy chain variable region consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, SEQ ID NOs: 4, SEQ ID NOs: 6, SEQ ID NOs: 8, SEQ ID NOs: 10, SEQ ID NOs: 11, SEQ ID NOs: 13, SEQ ID NOs: 15, SEQ ID NOs: 17, SEQ ID NOs: 18, SEQ ID NOs: 19, SEQ ID NOs: 20, SEQ ID NOs: 23, SEQ ID NOs: 25, SEQ ID NOs: 107 or SEQ ID NOs: 109, and the light chain variable region consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 3, SEQ ID NOs: 5, SEQ ID NOs: 7, SEQ ID NOs: 9, SEQ ID NOs: 12, SEQ ID NOs: 14, SEQ ID NOs: 16, SEQ ID NOs: 21, SEQ ID NOs: 22, SEQ ID NOs: 24, SEQ ID NOs: 26, SEQ ID NOs: 108 or SEQ ID NOs: 110.

[0084] [Clause 68-1] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Clause 26, wherein the heavy chain variable region consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 11, 13, 15, 17, 18, 19, 20, 23, or 25, and the light chain variable region consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 5, 7, 9, 12, 14, 16, 21, 22, 24, or 26.

[0085] [Item 69] (1) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 2, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 3, (2) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 4, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 5, (3) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 6, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 7, (4) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 8, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 9, (5) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 10, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 7, (6) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 11, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 12 (7) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 13, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 14. (8) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 15, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 16. (9) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 17, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 9. (10) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 18, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 7. (11) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 19, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 9. (12) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 20, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 21. (13) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 20, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 22; (14) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 23, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 24; (15) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 25, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 26; (16) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 107, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 108;(17) The antibody-drug conjugate according to claim 26 or a pharmaceutically acceptable salt thereof, wherein the heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 109 and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 110.

[0086] [Item 69-1] (1) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 2, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 3, (2) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 4, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 5, (3) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 6, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 7, (4) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 8, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 9, (5) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 10, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 7, (6) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 11, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 12 (7) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 13, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 14. (8) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 15, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 16. (9) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 17, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 9. (10) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 18, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 7. (11) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 19, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 9. (12) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 20, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 21. (13) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 20, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 22, (14) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 23, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 24, (15) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 25, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 26, The antibody-drug conjugate according to item 26 or a pharmaceutically acceptable salt thereof.

[0087] [Clause 70] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to any one of Clauses 44 to 57, wherein the antibody comprises a heavy chain constant region of human IgG1, IgG2, IgG3, or IgG4, the heavy chain constant region having amino acid substitutions at one to three positions selected from the group consisting of EU numbering 234, 235, 237, 297, 329, and 331.

[0088] [Clause 71] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Claim 70, wherein the antibody comprises a heavy chain constant region selected from the group consisting of the amino acid sequence of SEQ ID NO: 66, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, or SEQ ID NO: 101, a heavy chain constant region of human IgG2 consisting of the amino acid sequence of SEQ ID NO: 91, or SEQ ID NO: 92, a heavy chain constant region of human IgG3 consisting of the amino acid sequence of SEQ ID NO: 93, and a heavy chain constant region of human IgG4 consisting of the amino acid sequence of SEQ ID NO: 94, or SEQ ID NO: 95, wherein the heavy chain constant region may have amino acid substitutions at 1 to 3 positions selected from the group consisting of EU numbering positions 234, 235, 237, 297, 329, and 331.

[0089] [Clause 72] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Claim 70 or Claim 71, wherein the heavy chain constant region of human IgG1 comprises the amino acid sequence of SEQ ID NO: 66, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 101, and the heavy chain constant region may have one to three amino acid substitutions selected from the group consisting of: (1) substitution of the 234th amino acid of EU numbering to alanine or phenylalanine; (2) substitution of the 235th amino acid of EU numbering to alanine or glutamic acid; (3) substitution of the 237th amino acid of EU numbering to alanine; (4) substitution of the 297th amino acid of EU numbering to alanine, glutamine or glycine; (5) substitution of the 329th amino acid of EU numbering to glycine; and (6) substitution of the 331st amino acid of EU numbering to serine.

[0090] [Item 73] The heavy chain constant region of human IgG1 consists of the amino acid sequence of SEQ ID NO: 66, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 101, wherein the heavy chain constant region is: (1) a substitution of the 234th amino acid of EU numbering to alanine, and a substitution of the 235th amino acid of EU numbering to alanine, (2) a substitution of the 234th amino acid of EU numbering to alanine, a substitution of the 235th amino acid of EU numbering to alanine, and a substitution of the 237th amino acid of EU numbering to alanine, (3) a substitution of the 234th amino acid of EU numbering to alanine, a substitution of the 235th amino acid of EU numbering to alanine, and a substitution of the 329th amino acid of EU numbering to glycine (4) substitution of the 234th amino acid of the EU numbering to phenylalanine, substitution of the 235th amino acid of the EU numbering to glutamic acid, and substitution of the 331st amino acid of the EU numbering to serine, and (5) substitution of the 297th amino acid of the EU numbering to alanine, an antibody-drug conjugate according to any one of claims 70 to 72 or a pharmaceutically acceptable salt thereof.

[0091] [Clause 74] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to any one of Clauses 70 to 73, wherein the heavy chain constant region of human IgG1 comprises the amino acid sequence of SEQ ID NO: 66, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 101, and the heavy chain constant region may have (1) a substitution of the 234th amino acid of the EU numbering to alanine and a substitution of the 235th amino acid of the EU numbering to alanine, or (2) a substitution of the 297th amino acid of the EU numbering to alanine.

[0092] [Clause 75] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Claim 70, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, or SEQ ID NO: 51, the heavy chain constant region consists of the amino acid sequence of SEQ ID NO: 66, SEQ ID NO: 67, or SEQ ID NO: 68, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, or SEQ ID NO: 129.

[0093] [Clause 75-1] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Clause 70, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, or SEQ ID NO: 51, the heavy chain constant region consists of the amino acid sequence of SEQ ID NO: 66, SEQ ID NO: 67, or SEQ ID NO: 68, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, or SEQ ID NO: 65.

[0094] [Clause 76] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Claim 75, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 47, the heavy chain constant region consists of the amino acid sequence of SEQ ID NO: 66, SEQ ID NO: 67, or SEQ ID NO: 68, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 49 or SEQ ID NO: 58.

[0095] [Clause 77] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Clause 75, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 47, the heavy chain constant region consists of the amino acid sequence of SEQ ID NO: 66, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 58.

[0096] [Clause 78] The antibody-drug conjugate according to Claim 75 or a pharmaceutically acceptable salt thereof, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 47, the heavy chain constant region consists of the amino acid sequence of SEQ ID NO: 67, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 58.

[0097] [Clause 79] The antibody-drug conjugate according to Clause 75 or a pharmaceutically acceptable salt thereof, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 47, the heavy chain constant region consists of the amino acid sequence of SEQ ID NO: 68, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 58.

[0098] [Clause 80] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Claim 75, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 48, the heavy chain constant region consists of the amino acid sequence of SEQ ID NO: 66, SEQ ID NO: 67, or SEQ ID NO: 68, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 50 or SEQ ID NO: 61.

[0099] [Clause 81] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Claim 75, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 48, the heavy chain constant region consists of the amino acid sequence of SEQ ID NO: 66, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 61.

[0100] [Clause 82] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Claim 75, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 48, the heavy chain constant region consists of the amino acid sequence of SEQ ID NO: 67, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 61.

[0101] [Clause 83] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Clause 75, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 48, the heavy chain constant region consists of the amino acid sequence of SEQ ID NO: 68, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 61.

[0102] [Clause 84] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Claim 75, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 51, the heavy chain constant region consists of the amino acid sequence of SEQ ID NO: 66, SEQ ID NO: 67, or SEQ ID NO: 68, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 53 or SEQ ID NO: 64.

[0103] [Clause 85] The antibody-drug conjugate according to Claim 75 or a pharmaceutically acceptable salt thereof, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 51, the heavy chain constant region consists of the amino acid sequence of SEQ ID NO: 66, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 64.

[0104] [Clause 86] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Clause 75, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 51, the heavy chain constant region consists of the amino acid sequence of SEQ ID NO: 67, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 64.

[0105] [Clause 87] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Clause 75, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 51, the heavy chain constant region consists of the amino acid sequence of SEQ ID NO: 68, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 64.

[0106] [Clause 88] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Claim 44, wherein the antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 81, SEQ ID NO: 82, or SEQ ID NO: 83, and a light chain consisting of the amino acid sequence of SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, or SEQ ID NO: 137.

[0107] [Clause 88-1] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Clause 44, wherein the antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 81, SEQ ID NO: 82, or SEQ ID NO: 83, and a light chain consisting of the amino acid sequence of SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 84, or SEQ ID NO: 85.

[0108] [Clause 89] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Claim 44, wherein the antibody is composed of a combination of a heavy chain and a light chain selected from the group consisting of: A) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 69, SEQ ID NO: 70 or SEQ ID NO: 71 and a light chain consisting of the amino acid sequence of SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136 or SEQ ID NO: 137; B) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 75, SEQ ID NO: 76 or SEQ ID NO: 77 and a light chain consisting of the amino acid sequence of SEQ ID NO: 78, SEQ ID NO: 79 or SEQ ID NO: 80; and C) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 81, SEQ ID NO: 82 or SEQ ID NO: 83 and a light chain consisting of the amino acid sequence of SEQ ID NO: 84 or SEQ ID NO: 85.

[0109] [Clause 89-1] The antibody-drug conjugate according to Clause 44 or a pharmaceutically acceptable salt thereof, wherein the antibody is composed of a combination of a heavy chain and a light chain selected from the group consisting of: A) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 69, SEQ ID NO: 70 or SEQ ID NO: 71 and a light chain consisting of the amino acid sequence of SEQ ID NO: 72, SEQ ID NO: 73 or SEQ ID NO: 74; B) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 75, SEQ ID NO: 76 or SEQ ID NO: 77 and a light chain consisting of the amino acid sequence of SEQ ID NO: 78, SEQ ID NO: 79 or SEQ ID NO: 80; and C) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 81, SEQ ID NO: 82 or SEQ ID NO: 83 and a light chain consisting of the amino acid sequence of SEQ ID NO: 84 or SEQ ID NO: 85.

[0110] [Clause 90] The antibody-drug conjugate according to Claim 89 or a pharmaceutically acceptable salt thereof, wherein the antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO: 69 and a light chain consisting of the amino acid sequence of SEQ ID NO: 73.

[0111] [Clause 91] The antibody-drug conjugate according to Claim 89 or a pharmaceutically acceptable salt thereof, wherein the antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO: 70 and a light chain consisting of the amino acid sequence of SEQ ID NO: 73.

[0112] [Clause 92] The antibody-drug conjugate according to Claim 89 or a pharmaceutically acceptable salt thereof, wherein the antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO: 71 and a light chain consisting of the amino acid sequence of SEQ ID NO: 73.

[0113] [Clause 93] The antibody-drug conjugate according to Claim 89 or a pharmaceutically acceptable salt thereof, wherein the antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO: 75 and a light chain consisting of the amino acid sequence of SEQ ID NO: 79.

[0114] [Clause 94] The antibody-drug conjugate according to Claim 89 or a pharmaceutically acceptable salt thereof, wherein the antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO: 76 and a light chain consisting of the amino acid sequence of SEQ ID NO: 79.

[0115] [Clause 95] The antibody-drug conjugate according to Claim 89 or a pharmaceutically acceptable salt thereof, wherein the antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO: 77 and a light chain consisting of the amino acid sequence of SEQ ID NO: 79.

[0116] [Clause 96] The antibody-drug conjugate according to Claim 89 or a pharmaceutically acceptable salt thereof, wherein the antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO: 81 and a light chain consisting of the amino acid sequence of SEQ ID NO: 85.

[0117] [Clause 97] The antibody-drug conjugate according to Clause 89 or a pharmaceutically acceptable salt thereof, wherein the antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO: 82 and a light chain consisting of the amino acid sequence of SEQ ID NO: 85.

[0118] [Clause 98] The antibody-drug conjugate according to Clause 89 or a pharmaceutically acceptable salt thereof, wherein the antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO: 83 and a light chain consisting of the amino acid sequence of SEQ ID NO: 85.

[0119] [Item 99] The antibody fragment is a Fab fragment, a Fab' fragment, F(ab') ２ An antibody-drug conjugate according to any one of claims 1 to 69, or a pharmaceutically acceptable salt thereof, which is a fragment, an Fv fragment, or an scFv fragment.

[0120] [Item 100] In formula (1), mAb has a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, and the heavy chain variable region and the light chain variable region consist of: (1) CDR-H1 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 27 and 28; (2) CDR-H2 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 29, 30, 31, 32, 33, 34, 35, 36 and 37; (3) CDR-H3 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 38, 39, 40, 41 and 42; (4) (A) SEQ ID NOs: 43; (B) SEQ ID NOs: 55; (C) SEQ ID NOs: 56; (D) SEQ ID NOs: 57 CDR-L1 consists of an amino acid sequence selected from the group consisting of: (E) an amino acid sequence in which the 11th amino acid in the amino acid sequence of SEQ ID NO: 43 is replaced with alanine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, arginine, or lysine; (F) an amino acid sequence in which the 11th amino acid in the amino acid sequence of SEQ ID NO: 55 is replaced with alanine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, or lysine; and (G) an amino acid sequence in which the 11th amino acid in the amino acid sequence of SEQ ID NO: 56 or SEQ ID NO: 57 is replaced with leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, arginine, or lysine; (5) CDR-L2 consists of the amino acid sequence of SEQ ID NO: 44; and (6) CDR-L3 consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 45 and SEQ ID NO: 46. An antibody or antibody fragment comprising a complementarity-determining region composed of the following: n is an integer from 1 to 8, L is a group represented by formula (L-1), p is 2, Z is a group represented by formula (Z-1), m is 1, and Q is a phenyl group, which may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４R may be substituted with one substituent selected from the group consisting of alkoxy groups. １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３ The antibody-drug conjugate according to claim 1 or a pharmaceutically acceptable salt thereof, wherein AA is D-Glu, and may be substituted with one substituent selected from the group consisting of alkoxy groups.

[0121] [Item 101] In formula (1), mAb has a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, and the heavy chain variable region and the light chain variable region are A) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; B) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 55, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; C) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, D) CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 56, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; D) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 57, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; E) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 30, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 39, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46;F) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 31, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; G) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 30, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; H) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; I) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 55, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; J) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 56, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; K) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 57, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46;L) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; M) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 28, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 33, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; N) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 34, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; O) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 35, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; P) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 36, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; Q) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 34, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46;Alternatively, an antibody or antibody fragment comprising a complementation-determining region consisting of CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 37, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46, wherein n is an integer from 1 to 8, L is a group represented by formula (L-1), p is 2, Z is a group represented by formula (Z-1), m is 1, and Q is a phenyl group, which may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ R may be substituted with one substituent selected from the group consisting of alkoxy groups. １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３ The antibody-drug conjugate according to claim 1 or a pharmaceutically acceptable salt thereof, wherein AA is D-Glu, and may be substituted with one substituent selected from the group consisting of alkoxy groups.

[0122] [Item 102] In formula (1), mAb is an antibody or antibody fragment thereof, wherein the heavy chain has a heavy chain variable region and the light chain has a light chain variable region, the heavy chain variable region consists of an amino acid sequence having 95% or more sequence identity with the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 51 or SEQ ID NO: 52, and the light chain variable region consists of an amino acid sequence having 95% or more sequence identity with the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64 or SEQ ID NO: 65, n is an integer from 1 to 8, L is a group represented by formula (L-1), p is 2, Z is a group represented by formula (Z-1), m is 1, Q is a phenyl group, the phenyl group may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ R may be substituted with one substituent selected from the group consisting of alkoxy groups. １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３ The antibody-drug conjugate according to claim 1 or a pharmaceutically acceptable salt thereof, wherein AA is D-Glu, and may be substituted with one substituent selected from the group consisting of alkoxy groups.

[0123] [Item 103] In formula (1), mAb is an antibody or antibody fragment thereof having a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, wherein the heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 51 or SEQ ID NO: 52, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64 or SEQ ID NO: 65, n is an integer from 1 to 8, L is a group represented by formula (L-1), p is 2, Z is a group represented by formula (Z-1), m is 1, Q is a phenyl group, and the phenyl group may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ R may be substituted with one substituent selected from the group consisting of alkoxy groups. １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３ The antibody-drug conjugate according to claim 1 or a pharmaceutically acceptable salt thereof, wherein AA is D-Glu, and may be substituted with one substituent selected from the group consisting of alkoxy groups.

[0124] [Item 104] In formula (1), mAb is an antibody or antibody fragment composed of a combination of a heavy chain and a light chain selected from the group consisting of: A) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 69, SEQ ID NO: 70 or SEQ ID NO: 71 and a light chain consisting of the amino acid sequence of SEQ ID NO: 72, SEQ ID NO: 73 or SEQ ID NO: 74; B) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 75, SEQ ID NO: 76 or SEQ ID NO: 77 and a light chain consisting of the amino acid sequence of SEQ ID NO: 78, SEQ ID NO: 79 or SEQ ID NO: 80; and C) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 81, SEQ ID NO: 82 or SEQ ID NO: 83 and a light chain consisting of the amino acid sequence of SEQ ID NO: 84 or SEQ ID NO: 85, where n is an integer from 1 to 8, L is a group represented by formula (L-1), p is 2, Z is a group represented by formula (Z-1), m is 1, and Q is a phenyl group, which may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ R may be substituted with one substituent selected from the group consisting of alkoxy groups. １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３ The antibody-drug conjugate according to claim 1 or a pharmaceutically acceptable salt thereof, wherein AA is D-Glu, and may be substituted with one substituent selected from the group consisting of alkoxy groups.

[0125] [Item 105] In formula (1), mAb is an antibody or antibody fragment composed of a combination of a heavy chain and a light chain selected from the group consisting of: A) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 69, SEQ ID NO: 70, or SEQ ID NO: 71 and a light chain consisting of the amino acid sequence of SEQ ID NO: 73; B) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 75, SEQ ID NO: 76, or SEQ ID NO: 77 and a light chain consisting of the amino acid sequence of SEQ ID NO: 79; and C) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 81, SEQ ID NO: 82, or SEQ ID NO: 83 and a light chain consisting of the amino acid sequence of SEQ ID NO: 85, where n is an integer from 1 to 8, L is a group represented by formula (L-1), p is 2, Z is a group represented by formula (Z-1), m is 1, and Q is a phenyl group, which may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ R may be substituted with one substituent selected from the group consisting of alkoxy groups. １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３ The antibody-drug conjugate according to claim 1 or a pharmaceutically acceptable salt thereof, wherein AA is D-Glu, and may be substituted with one substituent selected from the group consisting of alkoxy groups.

[0126] [Item 106] In formula (1), mAb has a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, and the heavy chain variable region and the light chain variable region consist of: (1) CDR-H1 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 27 and SEQ ID NOs: 28; (2) CDR-H2 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 29, SEQ ID NOs: 30, SEQ ID NOs: 31, SEQ ID NOs: 32, SEQ ID NOs: 33, SEQ ID NOs: 34, SEQ ID NOs: 35, SEQ ID NOs: 36 and SEQ ID NOs: 37; (3) CDR-H3 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 38, SEQ ID NOs: 39, SEQ ID NOs: 40, SEQ ID NOs: 41 and SEQ ID NOs: 42; (4) (A) SEQ ID NOs: 43; (B) SEQ ID NOs: 55; (C) SEQ ID NOs: 56; (D) SEQ ID NOs: 57 CDR-L1 consists of an amino acid sequence selected from the group consisting of: (E) an amino acid sequence in which the 11th amino acid in the amino acid sequence of SEQ ID NO: 43 is replaced with alanine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, arginine, or lysine; (F) an amino acid sequence in which the 11th amino acid in the amino acid sequence of SEQ ID NO: 55 is replaced with alanine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, or lysine; and (G) an amino acid sequence in which the 11th amino acid in the amino acid sequence of SEQ ID NO: 56 or SEQ ID NO: 57 is replaced with leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, arginine, or lysine; (5) CDR-L2 consists of the amino acid sequence of SEQ ID NO: 44; and (6) CDR-L3 consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 45 and SEQ ID NO: 46. An antibody or antibody fragment comprising a complementation-determining region composed of the following, where n is an integer from 1 to 8, L is a group represented by formula (L-3) or formula (L-4), p is an integer from 2 to 5, AB is a peptide residue selected from the group consisting of -Val-Cit-, -Gly-Gly-Phe-Gly-, -Ala-Ala-, -Glu-Ala-Ala-, -Gly-Asn-, -Asn- and -Glu-Asn-, and Z is a group represented by formula (Z-2),m is 0 or 1, except when m is 0, (AA) ｍ C is a hydroxyl group, and Q is a phenyl group or an indolyl group, and the phenyl group and the indolyl group may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. ２ However, hydrogen atoms, halogen atoms, C １－３ It is an alkyl group or a methoxy group, and AA is a group derived from D-Glu or a compound represented by formula (AA-2), R １ｄ and R １ｅ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, p ２ An antibody-drug conjugate or a pharmaceutically acceptable salt thereof as described in item 1, wherein the ratio is 1 or 2.

[0127] [Item 107] In formula (1), mAb has a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, and the heavy chain variable region and the light chain variable region are A) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; B) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 55, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; C) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, D) CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 56, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; D) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 57, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; E) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 30, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 39, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46;F) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 31, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; G) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 30, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; H) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; I) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 55, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; J) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 56, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; K) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 57, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46;L) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; M) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 28, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 33, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; N) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 34, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; O) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 35, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; P) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 36, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; Q) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 34, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46;Alternatively, an antibody or antibody fragment thereof comprising a complementation determining region consisting of R) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 37, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46, where n is an integer from 1 to 8, L is a group represented by formula (L-3) or formula (L-4), p is an integer from 2 to 5, AB is a peptide residue selected from the group consisting of -Val-Cit-, -Gly-Gly-Phe-Gly-, -Ala-Ala-, -Glu-Ala-Ala-, -Gly-Asn-, -Asn-, and -Glu-Asn-, and Z is a group represented by formula (Z-2), m is 0 or 1, except when m is 0, (AA); ｍ C is a hydroxyl group, and Q is a phenyl group or an indolyl group, and the phenyl group and the indolyl group may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. ２ However, hydrogen atoms, halogen atoms, C １－３ It is an alkyl group or a methoxy group, and AA is a group derived from D-Glu or a compound represented by formula (AA-2), R １ｄ and R １ｅ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, p ２ An antibody-drug conjugate or a pharmaceutically acceptable salt thereof as described in item 1, wherein the ratio is 1 or 2.

[0128] [Item 108] In formula (1), mAb is an antibody or antibody fragment thereof, having a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, wherein the heavy chain variable region consists of an amino acid sequence having 95% or more sequence identity with the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 51 or SEQ ID NO: 52, and the light chain variable region consists of an amino acid sequence having 95% or more sequence identity with the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64 or SEQ ID NO: 65, n is an integer from 1 to 8, L is a group represented by formula (L-3) or formula (L-4), and p is an integer from 2 to 5. AB is a peptide residue selected from the group consisting of -Val-Cit-, -Gly-Gly-Phe-Gly-, -Ala-Ala-, -Glu-Ala-Ala-, -Gly-Asn-, -Asn-, and -Glu-Asn-, Z is a group represented by formula (Z-2), and m is 0 or 1, provided that if m is 0, then (AA) ｍ C is a hydroxyl group, and Q is a phenyl group or an indolyl group, and the phenyl group and the indolyl group may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. ２ However, hydrogen atoms, halogen atoms, C １－３ It is an alkyl group or a methoxy group, and AA is a group derived from D-Glu or a compound represented by formula (AA-2), R １ｄ and R １ｅ However, each is independent of a hydrogen atom or C １－３It is an alkyl group, p ２ An antibody-drug conjugate or a pharmaceutically acceptable salt thereof as described in item 1, wherein the ratio is 1 or 2.

[0129] [Item 109] In formula (1), mAb is an antibody or antibody fragment thereof having a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, wherein the heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 51 or SEQ ID NO: 52, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64 or SEQ ID NO: 65, n is an integer from 1 to 8, L is a group represented by formula (L-3) or formula (L-4), and p is an integer from 2 to 5. AB is a peptide residue selected from the group consisting of -Val-Cit-, -Gly-Gly-Phe-Gly-, -Ala-Ala-, -Glu-Ala-Ala-, -Gly-Asn-, -Asn-, and -Glu-Asn-, Z is a group represented by formula (Z-2), and m is 0 or 1, provided that if m is 0, then (AA) ｍ C is a hydroxyl group, and Q is a phenyl group or an indolyl group, and the phenyl group and the indolyl group may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. ２ However, hydrogen atoms, halogen atoms, C １－３ It is an alkyl group or a methoxy group, and AA is a group derived from D-Glu or a compound represented by formula (AA-2), R １ｄ and R１ｅ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, p ２ An antibody-drug conjugate or a pharmaceutically acceptable salt thereof as described in item 1, wherein the ratio is 1 or 2.

[0130] [Item 110] In formula (1), mAb is an antibody or antibody fragment composed of a combination of a heavy chain and a light chain selected from the group consisting of: A) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 69, SEQ ID NO: 70 or SEQ ID NO: 71 and a light chain consisting of the amino acid sequence of SEQ ID NO: 72, SEQ ID NO: 73 or SEQ ID NO: 74; B) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 75, SEQ ID NO: 76 or SEQ ID NO: 77 and a light chain consisting of the amino acid sequence of SEQ ID NO: 78, SEQ ID NO: 79 or SEQ ID NO: 80; and C) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 81, SEQ ID NO: 82 or SEQ ID NO: 83 and a light chain consisting of the amino acid sequence of SEQ ID NO: 84 or SEQ ID NO: 85, n is an integer from 1 to 8, L is a group represented by formula (L-3) or formula (L-4), and p is an integer from 2 to 5. AB is a peptide residue selected from the group consisting of -Val-Cit-, -Gly-Gly-Phe-Gly-, -Ala-Ala-, -Glu-Ala-Ala-, -Gly-Asn-, -Asn-, and -Glu-Asn-, Z is a group represented by formula (Z-2), and m is 0 or 1, provided that if m is 0, then (AA) ｍ C is a hydroxyl group, and Q is a phenyl group or an indolyl group, and the phenyl group and the indolyl group may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. ２However, hydrogen atoms, halogen atoms, C １－３ It is an alkyl group or a methoxy group, and AA is a group derived from D-Glu or a compound represented by formula (AA-2), R １ｄ and R １ｅ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, p ２ An antibody-drug conjugate or a pharmaceutically acceptable salt thereof as described in item 1, wherein the ratio is 1 or 2.

[0131] [Item 111] In formula (1), mAb is an antibody or antibody fragment composed of a combination of a heavy chain and a light chain selected from the group consisting of: A) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 69, SEQ ID NO: 70 or SEQ ID NO: 71 and a light chain consisting of the amino acid sequence of SEQ ID NO: 73; B) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 75, SEQ ID NO: 76 or SEQ ID NO: 77 and a light chain consisting of the amino acid sequence of SEQ ID NO: 79; and C) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 81, SEQ ID NO: 82 or SEQ ID NO: 83 and a light chain consisting of the amino acid sequence of SEQ ID NO: 85; n is an integer from 1 to 8; L is a group represented by formula (L-3) or formula (L-4); and p is an integer from 2 to 5. AB is a peptide residue selected from the group consisting of -Val-Cit-, -Gly-Gly-Phe-Gly-, -Ala-Ala-, -Glu-Ala-Ala-, -Gly-Asn-, -Asn-, and -Glu-Asn-, Z is a group represented by formula (Z-2), and m is 0 or 1, provided that if m is 0, then (AA) ｍ C is a hydroxyl group, and Q is a phenyl group or an indolyl group, and the phenyl group and indolyl group may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. ２ However, hydrogen atoms, halogen atoms, C １－３ It is an alkyl group or a methoxy group, and AA is a group derived from D-Glu or a compound represented by formula (AA-2), R １ｄ and R １ｅ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, p ２ An antibody-drug conjugate or a pharmaceutically acceptable salt thereof as described in item 1, wherein the ratio is 1 or 2.

[0132] [Item 112] In formula (1), mAb has a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, and the heavy chain variable region and the light chain variable region consist of: (1) CDR-H1 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs. 27 and SEQ ID NOs. 28; (2) CDR-H2 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs. 29, SEQ ID NOs. 30, SEQ ID NOs. 31, SEQ ID NOs. 32, SEQ ID NOs. 33, SEQ ID NOs. 34, SEQ ID NOs. 35, SEQ ID NOs. 36 and SEQ ID NOs. 37; (3) CDR-H3 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs. 38, SEQ ID NOs. 39, SEQ ID NOs. 40, SEQ ID NOs. 41 and SEQ ID NOs. 42; (4) (A) SEQ ID NOs. 43; (B) SEQ ID NOs. 55; (C) SEQ ID NOs. 56; (D) SEQ ID NOs. 57 CDR-L1 consists of an amino acid sequence selected from the group consisting of: (E) an amino acid sequence in which the 11th amino acid in the amino acid sequence of SEQ ID NO: 43 is replaced with alanine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, arginine, or lysine; (F) an amino acid sequence in which the 11th amino acid in the amino acid sequence of SEQ ID NO: 55 is replaced with alanine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, or lysine; and (G) an amino acid sequence in which the 11th amino acid in the amino acid sequence of SEQ ID NO: 56 or SEQ ID NO: 57 is replaced with leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, arginine, or lysine; (5) CDR-L2 consists of the amino acid sequence of SEQ ID NO: 44; and (6) CDR-L3 consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 45 and SEQ ID NO: 46. An antibody or antibody fragment comprising a complementation-determining region composed of, where n is an integer from 1 to 8, L is a group represented by formula (L-3) or formula (L-4), p is an integer from 2 to 5, AB is a peptide residue selected from the group consisting of -Val-Cit-, -Gly-Gly-Phe-Gly-, -Ala-Ala-, -Glu-Ala-Ala-, -Gly-Asn-, -Asn- and -Glu-Asn-, and Z is a group represented by formula (Z-3),m is 0 or 1, except when m is 0, (AA) ｍ C is a hydroxyl group, and Q is a phenyl group or an indolyl group, and the phenyl group and the indolyl group may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ａ However, hydrogen atoms or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ｃ However, C １－３ It is an alkylene group, R ２ However, hydrogen atoms, halogen atoms, C １－３ It is an alkyl group or a methoxy group, and AA is a group derived from D-Glu or a compound represented by formula (AA-2), R １ｄ and R １ｅ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, p ２ An antibody-drug conjugate or a pharmaceutically acceptable salt thereof as described in item 1, wherein the ratio is 1 or 2.

[0133] [Item 113] In formula (1), mAb has a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, and the heavy chain variable region and the light chain variable region are A) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; B) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 55, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; C) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, D) CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 56, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; D) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 57, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; E) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 30, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 39, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46;F) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 31, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; G) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 30, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; H) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; I) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 55, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; J) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 56, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; K) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 57, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46;L) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; M) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 28, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 33, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; N) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 34, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; O) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 35, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; P) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 36, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; Q) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 34, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46;Alternatively, an antibody or antibody fragment thereof comprising a complementation determining region consisting of R) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 37, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46, where n is an integer from 1 to 8, L is a group represented by formula (L-3) or formula (L-4), p is an integer from 2 to 5, AB is a peptide residue selected from the group consisting of -Val-Cit-, -Gly-Gly-Phe-Gly-, -Ala-Ala-, -Glu-Ala-Ala-, -Gly-Asn-, -Asn-, and -Glu-Asn-, and Z is a group represented by formula (Z-3), m is 0 or 1, except when m is 0, (AA); ｍ C is a hydroxyl group, and Q is a phenyl group or an indolyl group, and the phenyl group and the indolyl group may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ａ However, hydrogen atoms or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ｃ However, C １－３ It is an alkylene group, R ２ However, hydrogen atoms, halogen atoms, C １－３ It is an alkyl group or a methoxy group, and AA is a group derived from D-Glu or a compound represented by formula (AA-2), R １ｄ and R １ｅ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, p ２ An antibody-drug conjugate or a pharmaceutically acceptable salt thereof as described in item 1, wherein the ratio is 1 or 2.

[0134] [Item 114] In formula (1), mAb is an antibody or antibody fragment thereof, having a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, wherein the heavy chain variable region consists of an amino acid sequence having 95% or more sequence identity with the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 51 or SEQ ID NO: 52, and the light chain variable region consists of an amino acid sequence having 95% or more sequence identity with the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64 or SEQ ID NO: 65, n is an integer from 1 to 8, L is a group represented by formula (L-3) or formula (L-4), and p is an integer from 2 to 5. AB is a peptide residue selected from the group consisting of -Val-Cit-, -Gly-Gly-Phe-Gly-, -Ala-Ala-, -Glu-Ala-Ala-, -Gly-Asn-, -Asn-, and -Glu-Asn-, Z is a group represented by formula (Z-3), and m is 0 or 1, provided that if m is 0, then (AA) ｍ C is a hydroxyl group, and Q is a phenyl group or an indolyl group, and the phenyl group and the indolyl group may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ａ However, hydrogen atoms or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ｃ However, C １－３ It is an alkylene group, R ２ However, hydrogen atoms, halogen atoms, C １－３ It is an alkyl group or a methoxy group, and AA is a group derived from D-Glu or a compound represented by formula (AA-2), R １ｄ and R１ｅ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, p ２ An antibody-drug conjugate or a pharmaceutically acceptable salt thereof as described in item 1, wherein the ratio is 1 or 2.

[0135] [Item 115] In formula (1), mAb is an antibody or antibody fragment thereof having a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, wherein the heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 51 or SEQ ID NO: 52, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64 or SEQ ID NO: 65, n is an integer from 1 to 8, L is a group represented by formula (L-3) or formula (L-4), and p is an integer from 2 to 5. AB is a peptide residue selected from the group consisting of -Val-Cit-, -Gly-Gly-Phe-Gly-, -Ala-Ala-, -Glu-Ala-Ala-, -Gly-Asn-, -Asn-, and -Glu-Asn-, Z is a group represented by formula (Z-3), and m is 0 or 1, provided that if m is 0, then (AA) ｍ C is a hydroxyl group, and Q is a phenyl group or an indolyl group, and the phenyl group and the indolyl group may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ａ However, hydrogen atoms or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ｃ However, C １－３ It is an alkylene group, R ２ However, hydrogen atoms, halogen atoms, C １－３It is an alkyl group or a methoxy group, and AA is a group derived from D-Glu or a compound represented by formula (AA-2), R １ｄ and R １ｅ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, p ２ An antibody-drug conjugate or a pharmaceutically acceptable salt thereof as described in item 1, wherein the ratio is 1 or 2.

[0136] [Item 116] In formula (1), mAb is an antibody or antibody fragment composed of a combination of a heavy chain and a light chain selected from the group consisting of: A) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 69, SEQ ID NO: 70 or SEQ ID NO: 71 and a light chain consisting of the amino acid sequence of SEQ ID NO: 72, SEQ ID NO: 73 or SEQ ID NO: 74; B) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 75, SEQ ID NO: 76 or SEQ ID NO: 77 and a light chain consisting of the amino acid sequence of SEQ ID NO: 78, SEQ ID NO: 79 or SEQ ID NO: 80; and C) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 81, SEQ ID NO: 82 or SEQ ID NO: 83 and a light chain consisting of the amino acid sequence of SEQ ID NO: 84 or SEQ ID NO: 85, n is an integer from 1 to 8, L is a group represented by formula (L-3) or formula (L-4), and p is an integer from 2 to 5. AB is a peptide residue selected from the group consisting of -Val-Cit-, -Gly-Gly-Phe-Gly-, -Ala-Ala-, -Glu-Ala-Ala-, -Gly-Asn-, -Asn-, and -Glu-Asn-, Z is a group represented by formula (Z-3), and m is 0 or 1, provided that if m is 0, then (AA) ｍ C is a hydroxyl group, and Q is a phenyl group or an indolyl group, and the phenyl group and the indolyl group may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ａ However, hydrogen atoms or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ｃ However, C １－３ It is an alkylene group, R ２ However, hydrogen atoms, halogen atoms, C １－３ It is an alkyl group or a methoxy group, and AA is a group derived from D-Glu or a compound represented by formula (AA-2), R １ｄ and R １ｅ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, p ２ An antibody-drug conjugate or a pharmaceutically acceptable salt thereof as described in item 1, wherein the ratio is 1 or 2.

[0137] [Item 117] In formula (1), mAb is an antibody or antibody fragment composed of a combination of a heavy chain and a light chain selected from the group consisting of: A) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 69, SEQ ID NO: 70 or SEQ ID NO: 71 and a light chain consisting of the amino acid sequence of SEQ ID NO: 73; B) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 75, SEQ ID NO: 76 or SEQ ID NO: 77 and a light chain consisting of the amino acid sequence of SEQ ID NO: 79; and C) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 81, SEQ ID NO: 82 or SEQ ID NO: 83 and a light chain consisting of the amino acid sequence of SEQ ID NO: 85; n is an integer from 1 to 8; L is a group represented by formula (L-3) or formula (L-4); and p is an integer from 2 to 5. AB is a peptide residue selected from the group consisting of -Val-Cit-, -Gly-Gly-Phe-Gly-, -Ala-Ala-, -Glu-Ala-Ala-, -Gly-Asn-, -Asn-, and -Glu-Asn-, Z is a group represented by formula (Z-3), and m is 0 or 1, provided that if m is 0, then (AA) ｍ C is a hydroxyl group, and Q is a phenyl group or an indolyl group, and the phenyl group and the indolyl group may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ａHowever, hydrogen atoms or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ｃ However, C １－３ It is an alkylene group, R ２ However, hydrogen atoms, halogen atoms, C １－３ It is an alkyl group or a methoxy group, and AA is a group derived from D-Glu or a compound represented by formula (AA-2), R １ｄ and R １ｅ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, p ２ An antibody-drug conjugate or a pharmaceutically acceptable salt thereof as described in item 1, wherein the ratio is 1 or 2.

[0138] [Item 118] It is expressed by the following formula, in the following formula, mAb has a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, and the heavy chain variable region and the light chain variable region are A) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; B) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 55, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; C) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, D) CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 56, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; D) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 57, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; E) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 30, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 39, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; F) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 31, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46;G) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 30, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; H) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; I) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 55, J) CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; J) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 56, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; K) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 57, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; L) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46;M) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 28, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 33, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; N) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 34, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; O) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 35, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; P) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 36, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; Q) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 34, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46;Alternatively, an antibody or antibody fragment thereof comprising a complementation-determining region composed of R) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 37, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46, wherein n is an integer from 1 to 8, the antibody-drug conjugate described in item 1 or a pharmaceutically acceptable salt thereof.

[0139] [Item 119] It is expressed by the following formula, in the following formula, The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to item 1, wherein mAb is an antibody or antibody fragment thereof having a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, wherein the heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 47, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 58, SEQ ID NO: 59, or SEQ ID NO: 60, and n is an integer from 1 to 8.

[0140] [Item 120] It is expressed by the following formula, in the following formula, The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to item 1, wherein mAb is an antibody or antibody fragment thereof having a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, wherein the heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 48, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 50, SEQ ID NO: 61, SEQ ID NO: 62, or SEQ ID NO: 63, and n is an integer from 1 to 8.

[0141] [Item 121] It is expressed by the following formula, in the following formula, The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to item 1, wherein mAb is an antibody or antibody fragment thereof having a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, wherein the heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 51 and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 53 or SEQ ID NO: 64, and n is an integer from 1 to 8.

[0142] [Item 122] It is expressed by the following formula, in the following formula, The antibody-drug conjugate described in item 1 or a pharmaceutically acceptable salt thereof, wherein mAb is an antibody or antibody fragment thereof, comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 69 and a light chain consisting of the amino acid sequence of SEQ ID NO: 73, and n is an integer from 1 to 8.

[0143] [Item 123] It is expressed by the following formula, in the following formula, The antibody-drug conjugate described in item 1 or a pharmaceutically acceptable salt thereof, wherein mAb is an antibody or antibody fragment thereof, comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 70 and a light chain consisting of the amino acid sequence of SEQ ID NO: 73, and n is an integer from 1 to 8.

[0144] [Item 124] It is expressed by the following formula, in the following formula, The antibody-drug conjugate described in item 1 or a pharmaceutically acceptable salt thereof, wherein mAb is an antibody or antibody fragment thereof, comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 71 and a light chain consisting of the amino acid sequence of SEQ ID NO: 73, and n is an integer from 1 to 8.

[0145] [Item 125] It is expressed by the following formula, in the following formula, The antibody-drug conjugate described in item 1 or a pharmaceutically acceptable salt thereof, wherein mAb is an antibody or antibody fragment thereof, comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 75 and a light chain consisting of the amino acid sequence of SEQ ID NO: 79, and n is an integer from 1 to 8.

[0146] [Item 126] It is expressed by the following formula, in the following formula, The antibody-drug conjugate described in item 1 or a pharmaceutically acceptable salt thereof, wherein mAb is an antibody or antibody fragment thereof, comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 76 and a light chain consisting of the amino acid sequence of SEQ ID NO: 79, and n is an integer from 1 to 8.

[0147] [Item 127] It is expressed by the following formula, in the following formula, The antibody-drug conjugate described in item 1 or a pharmaceutically acceptable salt thereof, wherein mAb is an antibody or antibody fragment thereof, comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 77 and a light chain consisting of the amino acid sequence of SEQ ID NO: 79, and n is an integer from 1 to 8.

[0148] [Item 128] It is expressed by the following formula, in the following formula, mAb has a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, and the heavy chain variable region and the light chain variable region are A) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; B) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 55, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; C) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, D) CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 56, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; D) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 57, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; E) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 30, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 39, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; F) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 31, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46;G) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 30, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; H) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; I) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 55, J) CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; J) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 56, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; K) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 57, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; L) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46;M) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 28, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 33, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; N) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 34, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; O) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 35, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; P) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 36, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; Q) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 34, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46;Alternatively, an antibody or antibody fragment thereof comprising a complementation-determining region composed of R) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 37, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46, wherein n is an integer from 1 to 8, the antibody-drug conjugate described in item 1 or a pharmaceutically acceptable salt thereof.

[0149] [Item 129] It is expressed by the following formula, in the following formula, The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to item 1, wherein mAb is an antibody or antibody fragment thereof having a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, wherein the heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 47, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 58, SEQ ID NO: 59, or SEQ ID NO: 60, and n is an integer from 1 to 8.

[0150] [Item 130] It is expressed by the following formula, in the following formula, The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to item 1, wherein mAb is an antibody or antibody fragment thereof having a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, wherein the heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 48, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 50, SEQ ID NO: 61, SEQ ID NO: 62, or SEQ ID NO: 63, and n is an integer from 1 to 8.

[0151] [Item 131] It is expressed by the following formula, in the following formula, The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to item 1, wherein mAb is an antibody or antibody fragment thereof having a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, wherein the heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 51 and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 53 or SEQ ID NO: 64, and n is an integer from 1 to 8.

[0152] [Item 132] It is expressed by the following formula, in the following formula, The antibody-drug conjugate described in item 1 or a pharmaceutically acceptable salt thereof, wherein mAb is an antibody or antibody fragment thereof, comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 69 and a light chain consisting of the amino acid sequence of SEQ ID NO: 73, and n is an integer from 1 to 8.

[0153] [Item 133] It is expressed by the following formula, in the following formula, The antibody-drug conjugate described in item 1 or a pharmaceutically acceptable salt thereof, wherein mAb is an antibody or antibody fragment thereof, comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 70 and a light chain consisting of the amino acid sequence of SEQ ID NO: 73, and n is an integer from 1 to 8.

[0154] [Item 134] It is expressed by the following formula, in the following formula, The antibody-drug conjugate described in item 1 or a pharmaceutically acceptable salt thereof, wherein mAb is an antibody or antibody fragment thereof, comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 71 and a light chain consisting of the amino acid sequence of SEQ ID NO: 73, and n is an integer from 1 to 8.

[0155] [Item 135] It is expressed by the following formula, in the following formula, The antibody-drug conjugate described in item 1 or a pharmaceutically acceptable salt thereof, wherein mAb is an antibody or antibody fragment thereof, comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 75 and a light chain consisting of the amino acid sequence of SEQ ID NO: 79, and n is an integer from 1 to 8.

[0156] [Item 136] It is expressed by the following formula, in the following formula, The antibody-drug conjugate described in item 1 or a pharmaceutically acceptable salt thereof, wherein mAb is an antibody or antibody fragment thereof, comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 76 and a light chain consisting of the amino acid sequence of SEQ ID NO: 79, and n is an integer from 1 to 8.

[0157] [Item 137] It is expressed by the following formula, in the following formula, The antibody-drug conjugate described in item 1 or a pharmaceutically acceptable salt thereof, wherein mAb is an antibody or antibody fragment thereof, comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 77 and a light chain consisting of the amino acid sequence of SEQ ID NO: 79, and n is an integer from 1 to 8.

[0158] [Item 138] It is expressed by the following formula, in the following formula, mAb has a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, and the heavy chain variable region and the light chain variable region are A) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; B) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 55, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; C) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, D) CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 56, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; D) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 57, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; E) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 30, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 39, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; F) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 31, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46;G) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 30, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; H) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; I) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 55, J) CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; J) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 56, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; K) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 57, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; L) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46;M) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 28, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 33, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; N) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 34, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; O) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 35, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; P) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 36, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; Q) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 34, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46;Alternatively, an antibody or antibody fragment thereof comprising a complementation-determining region composed of R) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 37, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46, wherein n is an integer from 1 to 8, the antibody-drug conjugate described in item 1 or a pharmaceutically acceptable salt thereof.

[0159] [Item 139] It is expressed by the following formula, in the following formula, The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to item 1, wherein mAb is an antibody or antibody fragment thereof having a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, wherein the heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 47, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 58, SEQ ID NO: 59, or SEQ ID NO: 60, and n is an integer from 1 to 8.

[0160] [Item 140] It is expressed by the following formula, in the following formula, The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to item 1, wherein mAb is an antibody or antibody fragment thereof having a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, wherein the heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 48, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 50, SEQ ID NO: 61, SEQ ID NO: 62, or SEQ ID NO: 63, and n is an integer from 1 to 8.

[0161] [Item 141] It is expressed by the following formula, in the following formula, The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to item 1, wherein mAb is an antibody or antibody fragment thereof having a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, wherein the heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 51 and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 53 or SEQ ID NO: 64, and n is an integer from 1 to 8.

[0162] [Item 142] It is expressed by the following formula, in the following formula, The antibody-drug conjugate described in item 1 or a pharmaceutically acceptable salt thereof, wherein mAb is an antibody or antibody fragment thereof, comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 69 and a light chain consisting of the amino acid sequence of SEQ ID NO: 73, and n is an integer from 1 to 8.

[0163] [Item 143] It is expressed by the following formula, in the following formula, The antibody-drug conjugate described in item 1 or a pharmaceutically acceptable salt thereof, wherein mAb is an antibody or antibody fragment thereof, comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 70 and a light chain consisting of the amino acid sequence of SEQ ID NO: 73, and n is an integer from 1 to 8.

[0164] [Item 144] It is expressed by the following formula, in the following formula, The antibody-drug conjugate described in item 1 or a pharmaceutically acceptable salt thereof, wherein mAb is an antibody or antibody fragment thereof, comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 71 and a light chain consisting of the amino acid sequence of SEQ ID NO: 73, and n is an integer from 1 to 8.

[0165] [Item 145] It is expressed by the following formula, in the following formula, The antibody-drug conjugate described in item 1 or a pharmaceutically acceptable salt thereof, wherein mAb is an antibody or antibody fragment thereof, comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 75 and a light chain consisting of the amino acid sequence of SEQ ID NO: 79, and n is an integer from 1 to 8.

[0166] [Item 146] It is expressed by the following formula, in the following formula, The antibody-drug conjugate described in item 1 or a pharmaceutically acceptable salt thereof, wherein mAb is an antibody or antibody fragment thereof, comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 76 and a light chain consisting of the amino acid sequence of SEQ ID NO: 79, and n is an integer from 1 to 8.

[0167] [Item 147] It is expressed by the following formula, in the following formula, The antibody-drug conjugate described in item 1 or a pharmaceutically acceptable salt thereof, wherein mAb is an antibody or antibody fragment thereof, comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 77 and a light chain consisting of the amino acid sequence of SEQ ID NO: 79, and n is an integer from 1 to 8.

[0168] [Item 148] It is expressed by the following formula, in the following formula, mAb has a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, and the heavy chain variable region and the light chain variable region are A) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; B) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 55, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; C) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, D) CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 56, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; D) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 57, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; E) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 30, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 39, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; F) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 31, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46;G) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 30, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; H) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; I) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 55, J) CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; J) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 56, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; K) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 57, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; L) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46;M) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 28, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 33, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; N) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 34, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; O) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 35, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; P) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 36, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; Q) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 34, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46;Alternatively, an antibody or antibody fragment thereof comprising a complementation-determining region composed of R) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 37, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46, wherein n is an integer from 1 to 8, the antibody-drug conjugate described in item 1 or a pharmaceutically acceptable salt thereof.

[0169] [Item 149] It is expressed by the following formula, in the following formula, The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to item 1, wherein mAb is an antibody or antibody fragment thereof having a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, wherein the heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 47, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 58, SEQ ID NO: 59, or SEQ ID NO: 60, and n is an integer from 1 to 8.

[0170] [Item 150] It is expressed by the following formula, in the following formula, The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to item 1, wherein mAb is an antibody or antibody fragment thereof having a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, wherein the heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 48, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 50, SEQ ID NO: 61, SEQ ID NO: 62, or SEQ ID NO: 63, and n is an integer from 1 to 8.

[0171] [Item 151] It is expressed by the following formula, in the following formula, The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to item 1, wherein mAb is an antibody or antibody fragment thereof having a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, wherein the heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 51 and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 53 or SEQ ID NO: 64, and n is an integer from 1 to 8.

[0172] [Item 152] It is expressed by the following formula, in the following formula, The antibody-drug conjugate described in item 1 or a pharmaceutically acceptable salt thereof, wherein mAb is an antibody or antibody fragment thereof, comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 69 and a light chain consisting of the amino acid sequence of SEQ ID NO: 73, and n is an integer from 1 to 8.

[0173] [Item 153] It is expressed by the following formula, in the following formula, The antibody-drug conjugate described in item 1 or a pharmaceutically acceptable salt thereof, wherein mAb is an antibody or antibody fragment thereof, comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 70 and a light chain consisting of the amino acid sequence of SEQ ID NO: 73, and n is an integer from 1 to 8.

[0174] [Item 154] It is expressed by the following formula, in the following formula, The antibody-drug conjugate described in item 1 or a pharmaceutically acceptable salt thereof, wherein mAb is an antibody or antibody fragment thereof, comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 71 and a light chain consisting of the amino acid sequence of SEQ ID NO: 73, and n is an integer from 1 to 8.

[0175] [Item 155] It is expressed by the following formula, in the following formula, The antibody-drug conjugate described in item 1 or a pharmaceutically acceptable salt thereof, wherein mAb is an antibody or antibody fragment thereof, comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 75 and a light chain consisting of the amino acid sequence of SEQ ID NO: 79, and n is an integer from 1 to 8.

[0176] [Item 156] It is expressed by the following formula, in the following formula, The antibody-drug conjugate described in item 1 or a pharmaceutically acceptable salt thereof, wherein mAb is an antibody or antibody fragment thereof, comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 76 and a light chain consisting of the amino acid sequence of SEQ ID NO: 79, and n is an integer from 1 to 8.

[0177] [Item 157] It is expressed by the following formula, in the following formula, The antibody-drug conjugate described in item 1 or a pharmaceutically acceptable salt thereof, wherein mAb is an antibody or antibody fragment thereof, comprising a heavy chain consisting of the amino acid sequence of SEQ ID NO: 77 and a light chain consisting of the amino acid sequence of SEQ ID NO: 79, and n is an integer from 1 to 8.

[0178] [Clause 158] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to any one of Clauses 1 to 157, characterized in that the antibody-drug conjugate or a pharmaceutically acceptable salt thereof binds to a CCR8 antigen present on the cell surface and is internalized into the cell.

[0179] [Item 159] A pharmaceutical composition comprising an antibody-drug conjugate or a pharmaceutically acceptable salt thereof as described in any one of items 1 to 158.

[0180] [Item 160] A pharmaceutical composition for treating cancer, comprising an antibody-drug conjugate or a pharmaceutically acceptable salt thereof as described in any one of items 1 to 158.

[0181] [Item 161] A pharmaceutical composition for removing CCR8-positive Treg cells, comprising an antibody-drug conjugate or a pharmaceutically acceptable salt thereof as described in any one of items 1 to 158.

[0182] [Item 162] An anticancer agent comprising an antibody-drug conjugate or a pharmaceutically acceptable salt thereof as described in any one of items 1 to 158.

[0183] [Item 163] The anticancer agent according to item 162, wherein the cancer is breast cancer, stomach cancer, cervical cancer, colorectal cancer, rectal cancer, glioma, lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, kidney cancer, skin cancer, thyroid cancer, bladder cancer, head and neck cancer, endometrial cancer, lung cancer, liver cancer, colon cancer, mesothelioma, multiple myeloma, melanoma, or leukemia.

[0184] [Item 164] Use of an antibody-drug conjugate or a pharmaceutically acceptable salt thereof as described in any one of items 1 to 158 for the manufacture of a cancer treatment agent.

[0185] [Clause 165] A method for treating cancer, comprising administering to a patient in need of treatment an antibody-drug conjugate or a pharmaceutically acceptable salt thereof as described in any one of Clauses 1 to 158.

[0186] [Clause 166] An antibody-drug conjugate or a pharmaceutically acceptable salt thereof as described in any one of Clauses 1 to 158, for use in the treatment of cancer.

[0187] [Item 167] An antibody-drug conjugate or a pharmaceutically acceptable salt thereof, as described in any one of items 1 to 158, for treating cancer in combination with one or more anticancer compounds selected from the group consisting of anticancer alkylating agents, anticancer antimetabolites, anticancer antibiotics, anticancer platinum-coordinate compounds, anticancer camptothecin derivatives, anticancer tyrosine kinase inhibitors, anticancer serine / threonine kinase inhibitors, anticancer phospholipid kinase inhibitors, anticancer monoclonal antibodies, interferons, biological response modifiers, hormones, cancer immunotherapy agents, epigenetics-related molecule inhibitors, autophagy inhibitors, angiogenesis inhibitors, and protein post-translational modification inhibitors.

[0188] [Clause 167-2] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Clause 167, wherein the anticancer compound is a cancer immunotherapy agent.

[0189] [Clause 167-3] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Clause 167-2, wherein the cancer immunotherapy agent is an immune checkpoint inhibitor.

[0190] [Clause 167-4] The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to Clause 167-3, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody.

[0191] [Item 168] A pharmaceutical composition comprising an antibody-drug conjugate or a pharmaceutically acceptable salt thereof as described in any one of items 1 to 158, and one or more anticancer agents selected from the group consisting of anticancer alkylating agents, anticancer antimetabolites, anticancer antibiotics, anticancer platinum-coordinate compounds, anticancer camptothecin derivatives, anticancer tyrosine kinase inhibitors, anticancer serine / threonine kinase inhibitors, anticancer phospholipid kinase inhibitors, anticancer monoclonal antibodies, interferons, biological response modifiers, hormones, cancer immunotherapy agents, epigenetics-related molecule inhibitors, autophagy inhibitors, angiogenesis inhibitors, and protein post-translational modification inhibitors.

[0192] [Clause 168-2] The pharmaceutical composition according to Clause 168, wherein the anticancer agent is a cancer immunotherapy agent.

[0193] [Clause 168-3] The pharmaceutical composition according to Clause 168-2, wherein the cancer immunotherapy agent is an immune checkpoint inhibitor.

[0194] [Clause 168-4] The pharmaceutical composition according to Clause 168-3, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody.

[0195] [Item 169] A kit for treating cancer comprising an antibody-drug conjugate or a pharmaceutically acceptable salt thereof as described in any one of items 1 to 158, and a drug selected from the group consisting of anticancer alkylating agents, anticancer antimetabolites, anticancer antibiotics, anticancer platinum-coordinate compounds, anticancer camptothecin derivatives, anticancer tyrosine kinase inhibitors, anticancer serine / threonine kinase inhibitors, anticancer phospholipid kinase inhibitors, anticancer monoclonal antibodies, interferons, biological response modifiers, hormones, cancer immunotherapy agents, epigenetics-related molecule inhibitors, autophagy inhibitors, angiogenesis inhibitors, and protein post-translational modification inhibitors.

[0196] [Item 169-2] The kit for treating cancer according to item 169, wherein the drug is a cancer immunotherapy agent.

[0197] [Item 169-3] A kit for treating cancer according to item 169-2, wherein the cancer immunotherapy agent is an immune checkpoint inhibitor.

[0198] [Item 169-4] A kit for treating cancer according to item 169-3, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody.

[0199] [Item 170] CDR-H1 having a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, wherein the heavy chain variable region and the light chain variable region consist of an amino acid sequence selected from the group consisting of (1) SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 111, and an amino acid sequence in which one or two amino acids are deleted, substituted, inserted and / or added in the amino acid sequence of SEQ ID NO: 27, SEQ ID NO: 28, or SEQ ID NO: 111, (2) CDR-H2 having an amino acid sequence selected from the group consisting of SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, and an amino acid sequence in which one or two amino acids are deleted, substituted, inserted and / or added in the amino acid sequence of SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, or SEQ ID NO: 37, (3) CDR-H3 consisting of an amino acid sequence selected from the group consisting of amino acid sequences in which one or two amino acids are deleted, substituted, inserted and / or added in the amino acid sequences of SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 112, or SEQ ID NO: 113, (4) CDR-L1 consisting of an amino acid sequence selected from the group consisting of amino acid sequences in which one or two amino acids are deleted, substituted, inserted and / or added in the amino acid sequences of SEQ ID NO: 43, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, and SEQ ID NO: 43, SEQ ID NO: 55, SEQ ID NO: 56, or SEQ ID NO: 57, (5) CDR-L2 consisting of an amino acid sequence selected from the group consisting of amino acid sequences in which one or two amino acids are deleted, substituted, inserted and / or added in the amino acid sequence of SEQ ID NO: 44, and SEQ ID NO: 44, and (6) An antibody or antibody fragment that binds to CCR8, comprising a complementarity-determining region consisting of CDR-L3, which is an amino acid sequence selected from the group consisting of SEQ ID NO: 45, SEQ ID NO: 46, and amino acid sequences in which one or two amino acids are deleted, substituted, inserted and / or added in the amino acid sequence of SEQ ID NO: 45 or SEQ ID NO: 46.

[0200] [Item 170-1] CDR-H1 having a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, wherein the heavy chain variable region and the light chain variable region consist of an amino acid sequence selected from the group consisting of (1) SEQ ID NO: 27, SEQ ID NO: 28, and amino acid sequences in which one or two amino acids are deleted, substituted, inserted and / or added in the amino acid sequence of SEQ ID NO: 27 or SEQ ID NO: 28, and (2) CDR-H2 having an amino acid sequence selected from the group consisting of SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, and amino acid sequences in which one or two amino acids are deleted, substituted, inserted and / or added in the amino acid sequence of SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36 or SEQ ID NO: 37, (3) CDR-H3 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 38, 39, 40, 41, 42, and SEQ ID NOs: 38, 39, 40, 41, or 42 in which one or two amino acids are deleted, substituted, inserted and / or added; (4) CDR-L1 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 43, 55, 56, 57, and SEQ ID NOs: 43, 55, 56, or 57 in which one or two amino acids are deleted, substituted, inserted and / or added; (5) CDR-L2 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 44, and SEQ ID NOs: 44 in which one or two amino acids are deleted, substituted, inserted and / or added; (6) An antibody or antibody fragment that binds to CCR8, comprising a complementarity-determining region consisting of CDR-L3, which is an amino acid sequence selected from the group consisting of SEQ ID NO: 45, SEQ ID NO: 46, and amino acid sequences in which one or two amino acids are deleted, substituted, inserted and / or added in the amino acid sequence of SEQ ID NO: 45 or SEQ ID NO: 46.

[0201] [Item 171] The complementarity determining region is: (1) CDR-H1 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 27, 28 and 111; (2) CDR-H2 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 29, 30, 31, 32, 33, 34, 35, 36 and 37; (3) CDR-H3 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 38, 39, 40, 41, 42, 112 and 113; (4) (A) SEQ ID NOs: 43; (B) SEQ ID NOs: 55; (C) SEQ ID NOs: 56; (D) SEQ ID NOs: 57; CDR-L1 consists of an amino acid sequence selected from the group consisting of: (E) an amino acid sequence in which the 11th amino acid in the amino acid sequence of SEQ ID NO: 43 is substituted with alanine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, arginine, asparagine, glutamine, threonine, valine, or lysine; (F) an amino acid sequence in which the 11th amino acid in the amino acid sequence of SEQ ID NO: 55 is substituted with alanine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, or lysine; and (G) an amino acid sequence in which the 11th amino acid in the amino acid sequence of SEQ ID NO: 56 or SEQ ID NO: 57 is substituted with leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, arginine, or lysine; (5) CDR-L2 consists of the amino acid sequence of SEQ ID NO: 44; and (6) The antibody or antibody fragment according to item 170, comprising CDR-L3, which consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 45 and SEQ ID NO: 46.

[0202] [Item 171-1] The complementarity determining region is an amino acid sequence in which (1) CDR-H1 consists of an amino acid sequence selected from the group consisting of SEQ ID NOs. 27 and SEQ ID NOs. 28, (2) CDR-H2 consists of an amino acid sequence selected from the group consisting of SEQ ID NOs. 29, SEQ ID NOs. 30, SEQ ID NOs. 31, SEQ ID NOs. 32, SEQ ID NOs. 33, SEQ ID NOs. 34, SEQ ID NOs. 35, SEQ ID NOs. 36 and SEQ ID NOs. 37, (3) CDR-H3 consists of an amino acid sequence selected from the group consisting of SEQ ID NOs. 38, SEQ ID NOs. 39, SEQ ID NOs. 40, SEQ ID NOs. 41 and SEQ ID NOs. 42, (4) an amino acid sequence in which the 11th amino acid in the amino acid sequences of (A) SEQ ID NOs. 43, (B) SEQ ID NOs. 55, (C) SEQ ID NOs. 56, (D) SEQ ID NOs. 57, and (E) SEQ ID NOs. 43 is substituted with alanine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, arginine, or lysine. The antibody or antibody fragment according to claim 170, comprising: (F) an amino acid sequence in which the 11th amino acid in the amino acid sequence of SEQ ID NO: 55 is substituted with alanine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, or lysine; and (G) an amino acid sequence in which the 11th amino acid in the amino acid sequence of SEQ ID NO: 56 or SEQ ID NO: 57 is substituted with leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, arginine, or lysine; (5) CDR-L2 an amino acid sequence in which the 11th amino acid in the amino acid sequence of SEQ ID NO: 44; and (6) CDR-L3 an amino acid sequence in which the 10th amino acid in the amino acid sequence of SEQ ID NO: 45 and SEQ ID NO: 46.

[0203] [Clause 172] The antibody or antibody fragment according to Clause 170 or 171, wherein CDR-H1 consists of the amino acid sequence of SEQ ID NO: 27.

[0204] [Clause 173] The antibody or antibody fragment according to any one of Clauses 170 to 172, wherein the CDR-H2 consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 35, and SEQ ID NO: 37.

[0205] [Clause 174] The antibody or antibody fragment according to any one of Clauses 170 to 173, wherein the CDR-H2 consists of the amino acid sequence of SEQ ID NO: 29 or SEQ ID NO: 32.

[0206] [Clause 175] The antibody or antibody fragment according to any one of Clauses 170 to 174, wherein the CDR-H3 consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 41, and SEQ ID NO: 42.

[0207] [Clause 176] The antibody or antibody fragment according to any one of claims 170 to 175, wherein the CDR-H3 comprises SEQ ID NO: 38 or SEQ ID NO: 42.

[0208] [Clause 177] The antibody or antibody fragment according to any one of Clauses 170 to 176, wherein the CDR-L1 comprises: (1) the amino acid sequence of SEQ ID NO: 43, SEQ ID NO: 55, SEQ ID NO: 56, or SEQ ID NO: 57; (2) the amino acid sequence of SEQ ID NO: 43 in which the 11th amino acid is replaced with alanine; (3) the amino acid sequence of SEQ ID NO: 55 in which the 11th amino acid is replaced with alanine; or (4) the amino acid sequence of SEQ ID NO: 56 or SEQ ID NO: 57 in which the 11th amino acid is replaced with arginine.

[0209] [Clause 178] The antibody or antibody fragment according to any one of Clauses 170 to 177, wherein the CDR-L1 consists of the amino acid sequence of SEQ ID NO: 43, SEQ ID NO: 55, SEQ ID NO: 56, or SEQ ID NO: 57.

[0210] [Item 179] The complementarity determining region is: A) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; B) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 55, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; C) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 56 A) CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; D) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 57, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45; E) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 30, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 39, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; F) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 31, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46;G) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 30, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; H) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; I) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 55, J) CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; J) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 56, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; K) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 57, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; L) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46;M) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 28, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 33, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; N) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 34, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; O) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 35, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; P) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 36, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; Q) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 34, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; or R) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 37, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, The antibody or antibody fragment according to item 170, comprising CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46.

[0211] [Clause 180] The antibody or antibody fragment according to Claim 170, wherein the complementarity determining region comprises CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45.

[0212] [Clause 181] The antibody or antibody fragment according to Clause 170, wherein the complementarity determining region is composed of CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 55, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45.

[0213] [Clause 182] The antibody or antibody fragment according to Claim 170, wherein the complementarity determining region is composed of CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 56, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45.

[0214] [Clause 183] The antibody or antibody fragment according to Clause 170, wherein the complementarity determining region is composed of CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 57, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 45.

[0215] [Clause 184] The antibody or antibody fragment according to Clause 170, wherein the complementarity determining region is composed of CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46.

[0216] [Clause 185] The antibody or antibody fragment according to Claim 170, wherein the complementarity determining region comprises CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 55, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46.

[0217] [Clause 186] The antibody or antibody fragment according to Claim 170, wherein the complementarity determining region is composed of CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 56, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46.

[0218] [Clause 187] The antibody or antibody fragment according to Clause 170, wherein the complementarity determining region comprises CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 57, CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46.

[0219] [Item 188] The antibody or antibody fragment according to item 170, wherein the antibody is a humanized antibody.

[0220] [Item 189] The light chain variable region is: (1) the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64 or SEQ ID NO: 65; (2) the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53 or SEQ ID NO: 54, in which the 34th amino acid is substituted with alanine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, arginine, asparagine, glutamine, threonine, valine or lysine; (3) the amino acid sequence of SEQ ID NO: 58, SEQ ID NO: 61 or SEQ ID NO: 64, in which the 34th amino acid is substituted with alanine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid or lysine; or (4) The antibody or antibody fragment according to item 188, comprising an amino acid sequence in which the 34th amino acid in the amino acid sequence of SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 62, or SEQ ID NO: 63 is substituted with leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, arginine, or lysine.

[0221] [Item 189-1] The light chain variable region is: (1) the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64 or SEQ ID NO: 65; (2) the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53 or SEQ ID NO: 54, in which the 34th amino acid is substituted with alanine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, arginine or lysine; (3) the amino acid sequence of SEQ ID NO: 58, SEQ ID NO: 61 or SEQ ID NO: 64, in which the 34th amino acid is substituted with alanine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid or lysine; or (4) The antibody or antibody fragment according to item 188, comprising an amino acid sequence in which the 34th amino acid in the amino acid sequence of SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 62, or SEQ ID NO: 63 is substituted with leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, arginine, or lysine.

[0222] [Clause 190] The antibody or antibody fragment according to Claim 188, wherein the heavy chain variable region consists of an amino acid sequence having 95% or more sequence identity with the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 51 or SEQ ID NO: 52, and the light chain variable region consists of an amino acid sequence having 95% or more sequence identity with the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64 or SEQ ID NO: 65.

[0223] [Clause 191] The antibody or antibody fragment according to Claim 188, wherein the heavy chain variable region consists of an amino acid sequence having 96% or more sequence identity with the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 51 or SEQ ID NO: 52, and the light chain variable region consists of an amino acid sequence having 96% or more sequence identity with the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64 or SEQ ID NO: 65.

[0224] [Clause 192] The antibody or antibody fragment according to Claim 188, wherein the heavy chain variable region consists of an amino acid sequence having 97% or more sequence identity with the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 51 or SEQ ID NO: 52, and the light chain variable region consists of an amino acid sequence having 97% or more sequence identity with the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64 or SEQ ID NO: 65.

[0225] [Clause 193] The antibody or antibody fragment according to Claim 188, wherein the heavy chain variable region consists of an amino acid sequence having 98% or more sequence identity with the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 51 or SEQ ID NO: 52, and the light chain variable region consists of an amino acid sequence having 98% or more sequence identity with the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64 or SEQ ID NO: 65.

[0226] [Clause 194] The antibody or antibody fragment according to Claim 188, wherein the heavy chain variable region consists of an amino acid sequence having 99% or more sequence identity with the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 51 or SEQ ID NO: 52, and the light chain variable region consists of an amino acid sequence having 99% or more sequence identity with the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64 or SEQ ID NO: 65.

[0227] [Clause 195] The antibody or antibody fragment according to Clause 188, wherein the heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 51 or SEQ ID NO: 52, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128 or SEQ ID NO: 129.

[0228] [Clause 195-1] The antibody or antibody fragment according to Clause 188, wherein the heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 51 or SEQ ID NO: 52, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64 or SEQ ID NO: 65.

[0229] [Clause 196] The antibody or antibody fragment according to Claim 188, wherein the heavy chain variable region consists of an amino acid sequence having 95% or more sequence identity with the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, or SEQ ID NO: 51, and the light chain variable region consists of an amino acid sequence having 95% or more sequence identity with the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, or SEQ ID NO: 65.

[0230] [Clause 197] The antibody or antibody fragment according to Claim 188, wherein the heavy chain variable region consists of an amino acid sequence having 96% or more sequence identity with the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, or SEQ ID NO: 51, and the light chain variable region consists of an amino acid sequence having 96% or more sequence identity with the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, or SEQ ID NO: 65.

[0231] [Clause 198] The antibody or antibody fragment according to Claim 188, wherein the heavy chain variable region consists of an amino acid sequence having 97% or more sequence identity with the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, or SEQ ID NO: 51, and the light chain variable region consists of an amino acid sequence having 97% or more sequence identity with the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, or SEQ ID NO: 65.

[0232] [Clause 199] The antibody or antibody fragment according to Claim 188, wherein the heavy chain variable region consists of an amino acid sequence having 98% or more sequence identity with the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, or SEQ ID NO: 51, and the light chain variable region consists of an amino acid sequence having 98% or more sequence identity with the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, or SEQ ID NO: 65.

[0233] [Clause 200] The antibody or antibody fragment according to Claim 188, wherein the heavy chain variable region consists of an amino acid sequence having 99% or more sequence identity with the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, or SEQ ID NO: 51, and the light chain variable region consists of an amino acid sequence having 99% or more sequence identity with the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, or SEQ ID NO: 65.

[0234] [Clause 201] The antibody or antibody fragment according to Claim 188, wherein the heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, or SEQ ID NO: 51, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, or SEQ ID NO: 65.

[0235] [Clause 202] The antibody or antibody fragment according to Clause 188, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 47, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 49.

[0236] [Clause 203] The antibody or antibody fragment according to Claim 188, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 47, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 58.

[0237] [Clause 204] The antibody or antibody fragment according to Clause 188, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 47, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 59.

[0238] [Clause 205] The antibody or antibody fragment according to Clause 188, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 47, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 60.

[0239] [Clause 206] The antibody or antibody fragment according to Claim 188, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 48, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 50.

[0240] [Clause 207] The antibody or antibody fragment according to Clause 188, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 48, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 61.

[0241] [Clause 208] The antibody or antibody fragment according to Clause 188, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 48, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 62.

[0242] [Clause 209] The antibody or antibody fragment according to Clause 188, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 48, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 63.

[0243] [Clause 210] The antibody or antibody fragment according to Clause 188, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 51, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 53.

[0244] [Clause 211] The antibody or antibody fragment according to Clause 188, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 51, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 64.

[0245] [Clause 212] The antibody or antibody fragment according to Clause 170, wherein the heavy chain variable region consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, SEQ ID NOs: 4, SEQ ID NOs: 6, SEQ ID NOs: 8, SEQ ID NOs: 10, SEQ ID NOs: 11, SEQ ID NOs: 13, SEQ ID NOs: 15, SEQ ID NOs: 17, SEQ ID NOs: 18, SEQ ID NOs: 19, SEQ ID NOs: 20, SEQ ID NOs: 23, SEQ ID NOs: 25, SEQ ID NOs: 107, or SEQ ID NOs: 109, and the light chain variable region consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 3, SEQ ID NOs: 5, SEQ ID NOs: 7, SEQ ID NOs: 9, SEQ ID NOs: 12, SEQ ID NOs: 14, SEQ ID NOs: 16, SEQ ID NOs: 21, SEQ ID NOs: 22, SEQ ID NOs: 24, SEQ ID NOs: 26, SEQ ID NOs: 108, or SEQ ID NOs: 110.

[0246] [Item 212-1] The antibody or antibody fragment according to Item 170, wherein the heavy chain variable region consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 23, or SEQ ID NO: 25, and the light chain variable region consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 24, or SEQ ID NO: 26.

[0247] [Item 213] (1) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 2, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 3, (2) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 4, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 5, (3) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 6, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 7, (4) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 8, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 9, (5) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 10, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 7, (6) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 11, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 12 (7) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 13, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 14. (8) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 15, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 16. (9) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 17, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 9. (10) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 18, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 7. (11) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 19, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 9. (12) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 20, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 21. (13) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 20, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 22; (14) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 23, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 24; (15) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 25, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 26; (16) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 107, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 108;(17) The antibody or antibody fragment according to item 170, wherein the heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 109, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 110.

[0248] [Item 213] (1) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 2, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 3, (2) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 4, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 5, (3) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 6, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 7, (4) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 8, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 9, (5) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 10, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 7, (6) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 11, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 12 (7) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 13, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 14. (8) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 15, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 16. (9) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 17, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 9. (10) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 18, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 7. (11) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 19, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 9. (12) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 20, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 21. (13) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 20, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 22; (14) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 23, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 24; or (15) The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 25, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 26; The antibody or antibody fragment according to item 170.

[0249] [Clause 214] The antibody or antibody fragment according to any one of Claims 188 to 201, wherein the antibody comprises a heavy chain constant region of human IgG1, IgG2, IgG3, or IgG4, and the heavy chain constant region may have amino acid substitutions at one to three positions selected from the group consisting of EU numbering 234, 235, 237, 297, 329, and 331.

[0250] [Clause 215] The antibody or antibody fragment according to Claim 214, wherein the antibody comprises a heavy chain constant region selected from the group consisting of the amino acid sequence of SEQ ID NO: 66, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, or SEQ ID NO: 101, a heavy chain constant region of human IgG2 consisting of the amino acid sequence of SEQ ID NO: 91, or SEQ ID NO: 92, a heavy chain constant region of human IgG3 consisting of the amino acid sequence of SEQ ID NO: 93, and a heavy chain constant region of human IgG4 consisting of the amino acid sequence of SEQ ID NO: 94, or SEQ ID NO: 95, wherein the heavy chain constant region may have amino acid substitutions at 1 to 3 positions selected from the group consisting of EU numbering 234, 235, 237, 297, 329, and 331.

[0251] [Clause 216] The antibody or antibody fragment according to Claim 214 or Claim 215, wherein the heavy chain constant region of human IgG1 comprises the amino acid sequence of SEQ ID NO: 66, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 101, and the heavy chain constant region may have one to three amino acid substitutions selected from the group consisting of: (1) substitution of the 234th amino acid of EU numbering to alanine or phenylalanine, (2) substitution of the 235th amino acid of EU numbering to alanine or glutamic acid, (3) substitution of the 237th amino acid of EU numbering to alanine, (4) substitution of the 297th amino acid of EU numbering to alanine, glutamine or glycine, (5) substitution of the 329th amino acid of EU numbering to glycine, and (6) substitution of the 331st amino acid of EU numbering to serine.

[0252] [Item 217] The heavy chain constant region of human IgG1 consists of the amino acid sequence of SEQ ID NO: 66, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 101, wherein the heavy chain constant region is: (1) a substitution of the 234th amino acid of EU numbering to alanine, and a substitution of the 235th amino acid of EU numbering to alanine, (2) a substitution of the 234th amino acid of EU numbering to alanine, a substitution of the 235th amino acid of EU numbering to alanine, and a substitution of the 237th amino acid of EU numbering to alanine, (3) a substitution of the 234th amino acid of EU numbering to alanine, a substitution of the 235th amino acid of EU numbering to alanine, and a substitution of the 329th amino acid of EU numbering to glycine An antibody or antibody fragment according to any one of claims 214 to 216, which may have an amino acid substitution selected from the group consisting of (4) substitution of the 234th amino acid of the EU numbering to phenylalanine, substitution of the 235th amino acid of the EU numbering to glutamic acid and substitution of the 331st amino acid of the EU numbering to serine, and (5) substitution of the 297th amino acid of the EU numbering to alanine.

[0253] [Clause 218] The antibody or antibody fragment according to any one of Clauses 214 to 217, wherein the heavy chain constant region of human IgG1 comprises the amino acid sequence of SEQ ID NO: 66, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 101, and the heavy chain constant region may have (1) a substitution of the 234th amino acid of the EU numbering to alanine and a substitution of the 235th amino acid of the EU numbering to alanine, or (2) a substitution of the 297th amino acid of the EU numbering to alanine.

[0254] [Clause 219] The antibody or antibody fragment according to Clause 214, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, or SEQ ID NO: 51, the heavy chain constant region consists of the amino acid sequence of SEQ ID NO: 66, SEQ ID NO: 67, or SEQ ID NO: 68, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, or SEQ ID NO: 129.

[0255] [Clause 219-1] The antibody or antibody fragment according to Clause 214, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, or SEQ ID NO: 51, the heavy chain constant region consists of the amino acid sequence of SEQ ID NO: 66, SEQ ID NO: 67, or SEQ ID NO: 68, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, or SEQ ID NO: 65.

[0256] [Clause 220] The antibody or antibody fragment according to Claim 219, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 47, the heavy chain constant region consists of the amino acid sequence of SEQ ID NO: 66, SEQ ID NO: 67, or SEQ ID NO: 68, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 49 or SEQ ID NO: 58.

[0257] [Clause 221] The antibody or antibody fragment according to Claim 219, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 47, the heavy chain constant region consists of the amino acid sequence of SEQ ID NO: 66, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 58.

[0258] [Clause 222] The antibody or antibody fragment according to Claim 219, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 47, the heavy chain constant region consists of the amino acid sequence of SEQ ID NO: 67, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 58.

[0259] [Clause 223] The antibody or antibody fragment according to Clause 219, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 47, the heavy chain constant region consists of the amino acid sequence of SEQ ID NO: 68, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 58.

[0260] [Clause 224] The antibody or antibody fragment according to Clause 219, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 48, the heavy chain constant region consists of the amino acid sequence of SEQ ID NO: 66, SEQ ID NO: 67, or SEQ ID NO: 68, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 50 or SEQ ID NO: 61.

[0261] [Clause 225] The antibody or antibody fragment according to Clause 219, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 48, the heavy chain constant region consists of the amino acid sequence of SEQ ID NO: 66, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 61.

[0262] [Clause 226] The antibody or antibody fragment according to Claim 219, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 48, the heavy chain constant region consists of the amino acid sequence of SEQ ID NO: 67, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 61.

[0263] [Clause 227] The antibody or antibody fragment according to Clause 219, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 48, the heavy chain constant region consists of the amino acid sequence of SEQ ID NO: 68, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 61.

[0264] [Clause 228] The antibody or antibody fragment according to Clause 219, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 51, the heavy chain constant region consists of the amino acid sequence of SEQ ID NO: 66, SEQ ID NO: 67, or SEQ ID NO: 68, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 53 or SEQ ID NO: 64.

[0265] [Clause 229] The antibody or antibody fragment according to Clause 219, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 51, the heavy chain constant region consists of the amino acid sequence of SEQ ID NO: 66, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 64.

[0266] [Clause 230] The antibody or antibody fragment according to Claim 219, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 51, the heavy chain constant region consists of the amino acid sequence of SEQ ID NO: 67, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 64.

[0267] [Clause 231] The antibody or antibody fragment according to Clause 219, wherein the heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 51, the heavy chain constant region consists of the amino acid sequence of SEQ ID NO: 68, and the light chain variable region consists of the amino acid sequence of SEQ ID NO: 64.

[0268] [Clause 232] The antibody or antibody fragment according to Claim 188, wherein the antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 81, SEQ ID NO: 82, or SEQ ID NO: 83, and a light chain consisting of the amino acid sequence of SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, or SEQ ID NO: 137.

[0269] [Clause 232] The antibody or antibody fragment according to Claim 188, wherein the antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 81, SEQ ID NO: 82, or SEQ ID NO: 83, and a light chain consisting of the amino acid sequence of SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 84, or SEQ ID NO: 85.

[0270] [Clause 233] The antibody or antibody fragment according to Claim 188, wherein the antibody is composed of a combination of a heavy chain and a light chain selected from the group consisting of: A) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 69, SEQ ID NO: 70, or SEQ ID NO: 71, and a light chain consisting of the amino acid sequence of SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, or SEQ ID NO: 137; B) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 75, SEQ ID NO: 76, or SEQ ID NO: 77, and a light chain consisting of the amino acid sequence of SEQ ID NO: 78, SEQ ID NO: 79, or SEQ ID NO: 80; and C) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 81, SEQ ID NO: 82, or SEQ ID NO: 83, and a light chain consisting of the amino acid sequence of SEQ ID NO: 84, or SEQ ID NO: 85.

[0271] [Clause 233] The antibody or antibody fragment according to Claim 188, wherein the antibody is composed of a combination of a heavy chain and a light chain selected from the group consisting of: A) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 69, SEQ ID NO: 70, or SEQ ID NO: 71 and a light chain consisting of the amino acid sequence of SEQ ID NO: 72, SEQ ID NO: 73, or SEQ ID NO: 74; B) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 75, SEQ ID NO: 76, or SEQ ID NO: 77 and a light chain consisting of the amino acid sequence of SEQ ID NO: 78, SEQ ID NO: 79, or SEQ ID NO: 80; and C) a heavy chain consisting of the amino acid sequence of SEQ ID NO: 81, SEQ ID NO: 82, or SEQ ID NO: 83 and a light chain consisting of the amino acid sequence of SEQ ID NO: 84, or SEQ ID NO: 85.

[0272] [Clause 234] The antibody or antibody fragment according to Clause 233, wherein the antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO: 69 and a light chain consisting of the amino acid sequence of SEQ ID NO: 73.

[0273] [Clause 235] The antibody or antibody fragment according to Clause 233, wherein the antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO: 70 and a light chain consisting of the amino acid sequence of SEQ ID NO: 73.

[0274] [Clause 236] The antibody or antibody fragment according to Clause 233, wherein the antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO: 71 and a light chain consisting of the amino acid sequence of SEQ ID NO: 73.

[0275] [Clause 237] The antibody or antibody fragment according to Clause 233, wherein the antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO: 75 and a light chain consisting of the amino acid sequence of SEQ ID NO: 79.

[0276] [Clause 238] The antibody or antibody fragment according to Clause 233, wherein the antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO: 76 and a light chain consisting of the amino acid sequence of SEQ ID NO: 79.

[0277] [Clause 239] The antibody or antibody fragment according to Clause 233, wherein the antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO: 77 and a light chain consisting of the amino acid sequence of SEQ ID NO: 79.

[0278] [Clause 240] The antibody or antibody fragment according to Clause 233, wherein the antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO: 81 and a light chain consisting of the amino acid sequence of SEQ ID NO: 85.

[0279] [Clause 241] The antibody or antibody fragment according to Clause 233, wherein the antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO: 82 and a light chain consisting of the amino acid sequence of SEQ ID NO: 85.

[0280] [Clause 242] The antibody or antibody fragment according to Clause 233, wherein the antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO: 83 and a light chain consisting of the amino acid sequence of SEQ ID NO: 85.

[0281] [Item 243] The antibody fragment is a Fab fragment, a Fab' fragment, F(ab') ２ An antibody or antibody fragment according to any one of claims 170 to 213, which is a fragment, an Fv fragment, or an scFv fragment.

[0282] [Item 244] Use of an antibody or antibody fragment as described in any one of items 170 to 243 for the manufacture of a cancer treatment agent.

[0283] [Item 245] Compounds represented by formula (2) or pharmaceutically acceptable salts thereof [In the formula, L represents the group represented by the following formulas (L-1), (L-2), (L-3), or (L-4), (In the formula, p represents an integer from 1 to 5, AB represents a peptide residue consisting of 1 to 4 amino acids selected from the group consisting of glycine (Gly), phenylalanine (Phe), valine (Val), citrulline (Cit), asparagine (Asn), alanine (Ala), glutamic acid (Glu), and aspartic acid (Asp), the * part forms a bond with the nitrogen atom of the maleimide group, and the wavy line part forms a bond with Za) Za represents a group represented by formula (Z-1), formula (Za-2), or formula (Za-3): (In the formula, m represents an integer from 0 to 4, and Q represents a 6-10 member aromatic hydrocarbon ring group or a 5-10 member aromatic heterocyclic group, and the aromatic hydrocarbon ring group and the aromatic heterocyclic group may be substituted with halogen atoms, cyano groups, amino groups, or 1 to 3 fluorine atoms.) １－３ Alkyl groups, hydroxyl groups and C １－４ R may be substituted with one to five identical or different substituents selected from the group consisting of alkoxy groups. １ａ and R １ｂ Each of them is independently a hydrogen atom, C １－６ Alkyl alkyl group or C ３－８ Represents a saturated hydrocarbon ring group, and the alkyl group and the saturated hydrocarbon ring group are a halogen atom, a hydroxyl group, C １－３ Alkyl and C １－４ R may be substituted with one to five identical or different substituents selected from the group consisting of alkoxy groups. １ｃ C １－６ Represents an alkylene group, and the C １－６ Alkylene groups consist of a halogen atom, an amino group, a hydroxyl group, and C １－４ R may be substituted with one to five identical or different substituents selected from the group consisting of alkoxy groups. ２ａ is a hydrogen atom, a halogen atom, a hydroxyl group, C ２－３ Alkyl alkyl group, C １－４ Alkoxy group or C １－４AA represents a thioalkoxy group, where AA represents a group derived from a glutamic acid residue (Glu), an aspartic acid residue (Asp), a lysine residue (Lys), a serine residue (Ser), an ornithine residue (Orn), or a compound represented by formula (AA-1) or formula (AA-2). (In the formula, R １ｄ and R １ｅ Each of them is independently a hydrogen atom, C １－６ Represents an alkyl group or a polyethylene glycol group, and the C １－６ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－４ The substituents may be the same or different, selected from the group consisting of alkoxy groups, p １ represents an integer from 1 to 5, and p ２ (where represents an integer from 1 to 3) If there are multiple AAs, each AA may be the same as or different from the others, and the AAs may be linked to each other via amide bonds in a linear or branched manner. (AA) ｍ The nitrogen atom at the N-terminus or side chain forms an amide bond with the carbonyl group (#), provided that when Za is the group represented by formula (Z-1) and L is the group represented by formula (L-2), formula (L-3), or formula (L-4), m is an integer from 1 to 4, and at least one AA is derived from an ornithine residue or a compound represented by formula (AA-1), and when Za is the group represented by formula (Za-2) or formula (Za-3) and m is 0, (AA) ｍ (where is a hydroxyl group) (except for the following compounds or their pharmaceutically acceptable salts: (1) a compound in which Za is a group represented by formula (Z-1) and AA is a glutamic acid residue, an aspartic acid residue, or a lysine residue; (2) a compound in which Za is a group represented by formula (Z-1), L is a group represented by formula (L-3), and 1 to 4 amino acids constituting AB include glutamic acid or aspartic acid; and (3) a compound in which Za is a group represented by formula (Z-1), L is a group represented by formula (L-1), and m is 0).

[0284] [Clause 246] The compound described in Clause 245 or a pharmaceutically acceptable salt thereof, wherein AB is a peptide residue consisting of 1 to 4 amino acids selected from the group consisting of glycine (Gly), phenylalanine (Phe), valine (Val), citrulline (Cit), asparagine (Asn), alanine (Ala), and glutamic acid (Glu).

[0285] [Clause 247] The compound described in Clause 245 or Clause 246 or a pharmaceutically acceptable salt thereof, wherein AB is a peptide residue selected from the group consisting of -Val-Cit-, -Gly-Gly-Phe-Gly-, -Ala-Ala-, -Glu-Ala-Ala-, -Gly-Asn-, -Asn-, and -Glu-Asn-.

[0286] [Section 248] R １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－４ A compound according to any one of claims 245 to 247, or a pharmaceutically acceptable salt thereof, which may be substituted with one to three identical or different substituents selected from the group consisting of alkoxy groups.

[0287] [Item 249] A compound or a pharmaceutically acceptable salt thereof according to any one of items 245 to 248, wherein p is an integer between 2 and 5.

[0288] [Item 250] A compound or a pharmaceutically acceptable salt thereof according to any one of items 245 to 249, wherein m is an integer from 0 to 2.

[0289] [Item 251] AA is a group derived from D-Glu, D-Orn, D-Lys, or a compound represented by formula (AA-1) or formula (AA-2), R １ｄ and R １ｅ Each of them is independently a hydrogen atom, C １－６ The C is an alkyl group or a polyethylene glycol group. １－６ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－４A compound according to any one of claims 245 to 250 or a pharmaceutically acceptable salt thereof, which may be substituted with one to three identical or different substituents selected from the group consisting of alkoxy groups.

[0290] [Section 252] p １ is 3 or 4, p ２ A compound or a pharmaceutically acceptable salt thereof according to any one of items 245 to 251, wherein is 1 or 2.

[0291] [Item 253] Q is a phenyl group, a 1-naphthyl group, a 2-naphthyl group, a pyridyl group, a pyridazyl group, a pyrazyl group, a thienyl group, a pyrrole group, a thiazole group, an isothiazole group, a pyrazole group, a furanyl group, an oxazole group, an isoxazole group, a quinolinyl group, an isoquinolinyl group, a naphthilidinyl group, a quinazolinyl group, a benzofuranyl group, a benzothienyl group, an indolyl group, a 1H-indazolyl group, or a 2H-indazolyl group. The phenyl group, the 1-naphthyl group, the 2-naphthyl group, the pyridyl group, the pyridazyl group, the pyrazyl group, the thienyl group, the pyrrole group, the thiazole group, the isothiazole group, the pyrazole group, the furanyl group, the oxazole group, the isoxazole group, the quinolinyl group, the isoquinolinyl group, the naphthylidinyl group, the quinazolinyl group, the benzofuranyl group, the benzothienyl group, the indolyl group, the 1H-indazolyl group and the 2H-indazolyl group may be substituted with halogen atoms, cyano groups, amino groups, or 1 to 3 fluorine atoms. １－３ Alkyl groups, hydroxyl groups and C １－４ A compound according to any one of claims 245 to 252, or a pharmaceutically acceptable salt thereof, which may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups.

[0292] [Item 254] Q is a phenyl group, a thienyl group, a pyridyl group, or an indolyl group, and the phenyl group, the thienyl group, the pyridyl group, and the indolyl group may be substituted with a halogen atom, a cyano group, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl groups, hydroxyl groups and C １－４A compound according to any one of claims 245 to 253, or a pharmaceutically acceptable salt thereof, which may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups.

[0293] [Clause 255] A compound or a pharmaceutically acceptable salt thereof according to any one of Clauses 245 to 254, wherein m is 0 or 1.

[0294] [Clause 256] A compound according to any one of clauses 245 to 255 or a pharmaceutically acceptable salt thereof, wherein Za is a group represented by formula (Z-1).

[0295] [Clause 257] A compound according to any one of clauses 245 to 255 or a pharmaceutically acceptable salt thereof, wherein Za is a group represented by formula (Za-2).

[0296] [Clause 258] A compound according to any one of clauses 245 to 255 or a pharmaceutically acceptable salt thereof, wherein Za is a group represented by formula (Za-3).

[0297] [Item 259] L is a group represented by formula (L-1), formula (L-2), formula (L-3), or formula (L-4), p is an integer from 2 to 5, AB is a peptide residue consisting of 1 to 4 amino acids selected from the group consisting of glycine (Gly), phenylalanine (Phe), valine (Val), citrulline (Cit), asparagine (Asn), alanine (Ala), glutamic acid (Glu), and aspartic acid (Asp), Za is a group represented by formula (Z-1), m is 1, Q is a phenyl group, a thienyl group, a pyridyl group, or an indolyl group, and the phenyl group, the thienyl group, the pyridyl group, and the indolyl group may be substituted with a halogen atom, a cyano group, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl groups, hydroxyl groups and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups, and AA is a group derived from D-Orn or a compound represented by formula (AA-1) or formula (AA-2), １ｄ and R １ｅ However, each is independent of the hydrogen atom, C １－３ The C is an alkyl group or a polyethylene glycol group. １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－４ The substituents may be the same or different substituents selected from the group consisting of alkoxy groups, p １ is 3 or 4, p ２ A compound or a pharmaceutically acceptable salt thereof as described in item 245, wherein the ratio is 1 or 2.

[0298] [Item 260] L is a group represented by formula (L-1), formula (L-2), or formula (L-3), p is an integer from 2 to 5, AB is a peptide residue consisting of 1 to 4 amino acids selected from the group consisting of glycine (Gly), phenylalanine (Phe), valine (Val), citrulline (Cit), asparagine (Asn), alanine (Ala), glutamic acid (Glu), and aspartic acid (Asp), Za is a group represented by formula (Z-1), m is 1, and Q is a phenyl group or an indolyl group, the phenyl group and the indolyl group may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups, and AA is a group derived from D-Orn or a compound represented by formula (AA-1) or formula (AA-2), １ｄ and R １ｅ However, each is independent of the hydrogen atom, C １－３ It is an alkyl group or polyethylene glycol group, p １ is 3 or 4, p ２ A compound or a pharmaceutically acceptable salt thereof as described in item 245, wherein the ratio is 1 or 2.

[0299] [Item 261] L is a group represented by formula (L-1) or (L-2), p is 2, Za is a group represented by formula (Z-1), m is 1, and Q is a phenyl group or an indolyl group, the phenyl group and the indolyl group may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups, and AA is a group derived from a compound represented by formula (AA-1) or formula (AA-2), １ｄ and R １ｅ However, each is independent of the hydrogen atom, C １－３ It is an alkyl group or polyethylene glycol group, p １ is 3 or 4, p ２ A compound or a pharmaceutically acceptable salt thereof as described in item 245, wherein the ratio is 1 or 2.

[0300] [Item 262] L is a group represented by formula (L-2), p is 2, Za is a group represented by formula (Z-1), m is 1, and Q is a phenyl group or an indolyl group, and the phenyl group and the indolyl group may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ R may be substituted with one substituent selected from the group consisting of alkoxy groups. １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３ It may be substituted with one substituent selected from the group consisting of alkoxy groups, and AA is a group derived from the compound represented by formula (AA-1), R １ｄ and R １ｅ However, each is independent of the hydrogen atom, C １－３ It is an alkyl group or polyethylene glycol group, p １ A compound or a pharmaceutically acceptable salt thereof as described in item 245, wherein the ratio is 3 or 4.

[0301] [Item 263] L is a group represented by formula (L-2), p is 2, Za is a group represented by formula (Z-1), m is 1, and Q is a phenyl group or an indolyl group, and the phenyl group and the indolyl group may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ R may be substituted with one substituent selected from the group consisting of alkoxy groups. １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３ It may be substituted with one substituent selected from the group consisting of alkoxy groups, and AA is a group derived from the compound represented by formula (AA-1), R １ｄ and R １ｅHowever, each is independent of a hydrogen atom or C １－３ It is an alkyl group, p １ A compound or a pharmaceutically acceptable salt thereof as described in item 245, wherein the ratio is 3 or 4.

[0302] [Item 264] L is a group represented by formula (L-2), p is 2, Za is a group represented by formula (Z-1), m is 1, and Q is a phenyl group, which may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ R may be substituted with one substituent selected from the group consisting of alkoxy groups. １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３ It may be substituted with one substituent selected from the group consisting of alkoxy groups, and AA is a group derived from the compound represented by formula (AA-1), R １ｄ and R １ｅ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, p １ A compound or a pharmaceutically acceptable salt thereof as described in item 245, wherein the ratio is 3 or 4.

[0303] [Item 265] L is a group represented by formula (L-2), formula (L-3), or formula (L-4), p is an integer from 2 to 5, AB is a peptide residue consisting of 1 to 4 amino acids selected from the group consisting of glycine (Gly), phenylalanine (Phe), valine (Val), citrulline (Cit), asparagine (Asn), alanine (Ala), glutamic acid (Glu), and aspartic acid (Asp), Za is a group represented by formula (Za-2), m is 0 or 1, except when m is 0, (AA) ｍC is a hydroxyl group, and Q is a phenyl group, a thienyl group, a pyridyl group, or an indolyl group, and the phenyl group, the thienyl group, the pyridyl group, and the indolyl group may be substituted with a halogen atom, a cyano group, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl groups, hydroxyl groups and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. ２ａ However, hydrogen atoms, halogen atoms, hydroxyl groups, C ２－３ Alkyl alkyl group, C １－４ Alkoxy group or C １－４ It is a thioalkoxy group, where AA is a group derived from D-Glu, D-Orn, D-Lys, or a compound represented by formula (AA-1) or formula (AA-2), and R １ｄ and R １ｅ However, each is independent of the hydrogen atom, C １－３ The C is an alkyl group or a polyethylene glycol group. １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－４ The substituents may be the same or different substituents selected from the group consisting of alkoxy groups, p １ is 3 or 4, p ２ A compound or a pharmaceutically acceptable salt thereof as described in item 245, wherein the ratio is 1 or 2.

[0304] [Item 266] L is a group represented by formula (L-3) or formula (L-4), p is an integer from 2 to 5, AB is a peptide residue selected from the group consisting of -Val-Cit-, -Gly-Gly-Phe-Gly-, -Ala-Ala-, -Glu-Ala-Ala-, -Gly-Asn-, -Asn- and -Glu-Asn-, Za is a group represented by formula (Za-2), m is 0 or 1, except when m is 0, (AA) ｍ C is a hydroxyl group, and Q is a phenyl group or an indolyl group, and the phenyl group and the indolyl group may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. ２ａ However, hydrogen atoms, halogen atoms, C ２－３ The group is an alkyl group, a methoxy group, a methylthio group, an ethylthio group, or a tert-butylthio group, and AA is a group derived from D-Glu or a compound represented by formula (AA-2), R １ｄ and R １ｅ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, p ２ A compound or a pharmaceutically acceptable salt thereof as described in item 245, wherein the ratio is 1 or 2.

[0305] [Item 267] L is a group represented by formula (L-1), formula (L-2), formula (L-3), or formula (L-4), p is an integer from 2 to 5, AB is a peptide residue consisting of 1 to 4 amino acids selected from the group consisting of glycine (Gly), phenylalanine (Phe), valine (Val), citrulline (Cit), asparagine (Asn), alanine (Ala), glutamic acid (Glu), and aspartic acid (Asp), Za is a group represented by formula (Za-3), m is 0 or 1, except when m is 0, (AA) ｍ C is a hydroxyl group, and Q is a phenyl group, a thienyl group, a pyridyl group, or an indolyl group, and the phenyl group, the thienyl group, the pyridyl group, and the indolyl group may be substituted with a halogen atom, a cyano group, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl groups, hydroxyl groups and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ａ However, hydrogen atoms or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ｃ However, C １－６ It is an alkylene group, and the C １－６ Alkylene groups consist of a halogen atom, an amino group, a hydroxyl group, and C １－４ R may be substituted with one to five identical or different substituents selected from the group consisting of alkoxy groups. ２ａ However, hydrogen atoms, halogen atoms, hydroxyl groups, C ２－３ Alkyl alkyl group, C １－４ Alkoxy group or C １－４ It is a thioalkoxy group, where AA is a group derived from D-Glu, D-Orn, D-Lys, or a compound represented by formula (AA-1) or formula (AA-2), and R １ｄ and R １ｅ However, each is independent of the hydrogen atom, C １－３The C is an alkyl group or a polyethylene glycol group. １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－４ The substituents may be the same or different substituents selected from the group consisting of alkoxy groups, p １ is 3 or 4, p ２ A compound or a pharmaceutically acceptable salt thereof as described in item 245, wherein the ratio is 1 or 2.

[0306] [Item 268] L is a group represented by formula (L-3) or formula (L-4), p is an integer from 2 to 5, AB is a peptide residue selected from the group consisting of -Val-Cit-, -Gly-Gly-Phe-Gly-, -Ala-Ala-, -Glu-Ala-Ala-, -Gly-Asn-, -Asn- and -Glu-Asn-, Za is a group represented by formula (Za-3), m is 0 or 1, except when m is 0, (AA) ｍ C is a hydroxyl group, and Q is a phenyl group or an indolyl group, and the phenyl group and the indolyl group may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ａ However, hydrogen atoms or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ｃ However, C １－３ It is an alkylene group, and the C １－３ Alkylene groups consist of a halogen atom, an amino group, a hydroxyl group, and C １－４ R may be substituted with one to three identical or different substituents selected from the group consisting of alkoxy groups. ２ａ However, hydrogen atoms, halogen atoms, C ２－３The group is an alkyl group, a methoxy group, a methylthio group, an ethylthio group, or a tert-butylthio group, and AA is a group derived from D-Glu or a compound represented by formula (AA-2), R １ｄ and R １ｅ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, p ２ A compound or a pharmaceutically acceptable salt thereof as described in item 245, wherein the ratio is 1 or 2.

[0307] [Item 269] A compound described in Item 245 or a pharmaceutically acceptable salt thereof, represented by any of the following formulas.

[0308] [Item 270] Compounds represented by formula (Z-1a), formula (Z-2a), or formula (Z-3a), or pharmaceutically acceptable salts thereof. [In the formula, m represents an integer from 0 to 4, and Q represents a 6-10 member aromatic hydrocarbon ring group or a 5-10 member aromatic heterocyclic group, wherein the aromatic hydrocarbon ring group and the aromatic heterocyclic group may be substituted with halogen atoms, cyano groups, amino groups, or 1 to 3 fluorine atoms. １－３ Alkyl groups, hydroxyl groups and C １－４ R may be substituted with one to five identical or different substituents selected from the group consisting of alkoxy groups. １ａ and R １ｂ Each of them is independently a hydrogen atom, C １－６ Alkyl alkyl group or C ３－８ Represents a saturated hydrocarbon ring group, and the alkyl group and the saturated hydrocarbon ring group are a halogen atom, a hydroxyl group, C １－３ Alkyl and C １－４ R may be substituted with one to five identical or different substituents selected from the group consisting of alkoxy groups. １ｃ C １－６ Represents an alkylene group, and the C １－６ Alkylene groups consist of a halogen atom, an amino group, a hydroxyl group, and C １－４ R may be substituted with one to five identical or different substituents selected from the group consisting of alkoxy groups. ２ａ is a hydrogen atom, a halogen atom, a hydroxyl group, C ２－３Alkyl alkyl group, C １－４ Alkoxy group or C １－４ AA represents a thioalkoxy group, where AA represents a group derived from a glutamic acid residue (Glu), an aspartic acid residue (Asp), a lysine residue (Lys), a serine residue (Ser), an ornithine residue (Orn), or a compound represented by formula (AA-1) or formula (AA-2). (In the formula, R １ｄ and R １ｅ Each of them is independently a hydrogen atom, C １－６ Represents an alkyl group or a polyethylene glycol group, and the C １－６ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－４ The substituents may be the same or different, selected from the group consisting of alkoxy groups, p １ represents an integer from 1 to 5, and p ２ (where represents an integer from 1 to 3) If there are multiple AAs, each AA may be the same or different from the others, and the AAs are linked to each other via amide bonds in a linear or branched manner. (AA) ｍ The nitrogen atom at the N-terminus or side chain forms an amide bond with the carbonyl group (#), provided that m is 0, (AA) ｍ [wherein is a hydroxyl group] (except for compounds represented by formula (Z-1a) in which m is 0, or AA is a glutamic acid residue, an aspartic acid residue, or a lysine residue, or their pharmaceutically acceptable salts).

[0309] [Section 271] R １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－４ A compound according to claim 270 or a pharmaceutically acceptable salt thereof, which may be substituted with one to three identical or different substituents selected from the group consisting of alkoxy groups.

[0310] [Clause 272] A compound or a pharmaceutically acceptable salt thereof according to clause 270 or 271, wherein m is an integer from 0 to 2.

[0311] [Item 273] AA is a group derived from D-Glu, D-Orn, D-Lys, or a compound represented by formula (AA-1) or formula (AA-2), R １ｄ and R １ｅ Each of them is independently a hydrogen atom, C １－６ The C is an alkyl group or a polyethylene glycol group. １－６ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－４ A compound according to any one of claims 270 to 272, or a pharmaceutically acceptable salt thereof, which may be substituted with one to three identical or different substituents selected from the group consisting of alkoxy groups.

[0312] [Section 274] p １ is 3 or 4, p ２ A compound or a pharmaceutically acceptable salt thereof as described in any one of paragraphs 270 to 273, wherein is 1 or 2.

[0313] [Item 275] Q is a phenyl group, a 1-naphthyl group, a 2-naphthyl group, a pyridyl group, a pyridazyl group, a pyrazyl group, a thienyl group, a pyrrole group, a thiazole group, an isothiazole group, a pyrazole group, a furanyl group, an oxazole group, an isoxazole group, a quinolinyl group, an isoquinolinyl group, a naphthilidinyl group, a quinazolinyl group, a benzofuranyl group, a benzothienyl group, an indolyl group, a 1H-indazolyl group, or a 2H-indazolyl group. The phenyl group, the 1-naphthyl group, the 2-naphthyl group, the pyridyl group, the pyridazyl group, the pyrazyl group, the thienyl group, the pyrrole group, the thiazole group, the isothiazole group, the pyrazole group, the furanyl group, the oxazole group, the isoxazole group, the quinolinyl group, the isoquinolinyl group, the naphthylidinyl group, the quinazolinyl group, the benzofuranyl group, the benzothienyl group, the indolyl group, the 1H-indazolyl group and the 2H-indazolyl group may be substituted with halogen atoms, cyano groups, amino groups, or 1 to 3 fluorine atoms. １－３ Alkyl groups, hydroxyl groups and C １－４A compound according to any one of claims 270 to 274, or a pharmaceutically acceptable salt thereof, which may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups.

[0314] [Item 276] Q is a phenyl group, a thienyl group, a pyridyl group, or an indolyl group, and the phenyl group, the thienyl group, the pyridyl group, and the indolyl group may be substituted with a halogen atom, a cyano group, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl groups, hydroxyl groups and C １－４ A compound according to any one of claims 270 to 275, or a pharmaceutically acceptable salt thereof, which may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups.

[0315] [Clause 277] A compound or a pharmaceutically acceptable salt thereof according to any one of Clauses 270 to 276, wherein m is 0 or 1.

[0316] [Clause 278] A compound represented by formula (Z-1a) as described in any one of clauses 270 to 277, or a pharmaceutically acceptable salt thereof.

[0317] [Item 279] A compound represented by formula (Z-2a) as described in any one of items 270 to 277, or a pharmaceutically acceptable salt thereof.

[0318] [Clause 280] A compound represented by formula (Z-3a) as described in any one of clauses 270 to 277, or a pharmaceutically acceptable salt thereof.

[0319] [Item 281] Represented by formula (Z-1a), where m is 1, and Q is a phenyl group, a thienyl group, a pyridyl group, or an indolyl group, the phenyl group, the thienyl group, the pyridyl group, and the indolyl group may be substituted with a halogen atom, a cyano group, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl groups, hydroxyl groups and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups, and AA is a group derived from D-Orn or a compound represented by formula (AA-1) or formula (AA-2), １ｄ and R １ｅ However, each is independent of the hydrogen atom, C １－３ The C is an alkyl group or a polyethylene glycol group. １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－４ The substituents may be the same or different substituents selected from the group consisting of alkoxy groups, p １ is 3 or 4, p ２ A compound or a pharmaceutically acceptable salt thereof as described in item 270, wherein the ratio is 1 or 2.

[0320] [Item 282] Represented by formula (Z-1a), where m is 1 and Q is a phenyl group or an indolyl group, the phenyl group and the indolyl group may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups, and AA is a group derived from D-Orn or a compound represented by formula (AA-1) or formula (AA-2), １ｄ and R １ｅ However, each is independent of the hydrogen atom, C １－３ It is an alkyl group or polyethylene glycol group, p １ is 3 or 4, p ２A compound or a pharmaceutically acceptable salt thereof as described in item 270, wherein the ratio is 1 or 2.

[0321] [Item 283] Represented by formula (Z-1a), where m is 1 and Q is a phenyl group or an indolyl group, the phenyl group and the indolyl group may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ R may be substituted with one substituent selected from the group consisting of alkoxy groups. １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３ It may be substituted with one substituent selected from the group consisting of alkoxy groups, and AA is a group derived from the compound represented by formula (AA-1), and R １ｄ and R １ｅ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, p １ A compound or a pharmaceutically acceptable salt thereof as described in item 270, wherein the ratio is 3 or 4.

[0322] [Item 284] Represented by formula (Z-2a), where m is 0 or 1, except when m is 0, (AA) ｍ C is a hydroxyl group, and Q is a phenyl group, a thienyl group, a pyridyl group, or an indolyl group, and the phenyl group, the thienyl group, the pyridyl group, and the indolyl group may be substituted with a halogen atom, a cyano group, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl groups, hydroxyl groups and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－４R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. ２ａ However, hydrogen atoms, halogen atoms, hydroxyl groups, C ２－３ Alkyl alkyl group, C １－４ Alkoxy group or C １－４ It is a thioalkoxy group, where AA is a group derived from D-Glu, D-Orn, D-Lys, or a compound represented by formula (AA-1) or formula (AA-2), and R １ｄ and R １ｅ However, each is independent of the hydrogen atom, C １－３ The C is an alkyl group or a polyethylene glycol group. １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－４ The substituents may be the same or different substituents selected from the group consisting of alkoxy groups, p １ is 3 or 4, p ２ A compound or a pharmaceutically acceptable salt thereof as described in item 270, wherein the ratio is 1 or 2.

[0323] [Item 285] Represented by formula (Z-2a), where m is 0 or 1, except when m is 0, (AA) ｍ C is a hydroxyl group, and Q is a phenyl group or an indolyl group, and the phenyl group and the indolyl group may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. ２ａ However, hydrogen atoms, halogen atoms, C ２－３The group is an alkyl group, a methoxy group, a methylthio group, an ethylthio group, or a tert-butylthio group, and AA is a group derived from D-Glu or a compound represented by formula (AA-2), R １ｄ and R １ｅ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, p ２ A compound or a pharmaceutically acceptable salt thereof as described in item 270, wherein the ratio is 1 or 2.

[0324] [Item 286] Represented by formula (Z-3a), where m is 0 or 1, except when m is 0, (AA) ｍ C is a hydroxyl group, and Q is a phenyl group, a thienyl group, a pyridyl group, or an indolyl group, and the phenyl group, the thienyl group, the pyridyl group, and the indolyl group may be substituted with a halogen atom, a cyano group, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl groups, hydroxyl groups and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ａ However, hydrogen atoms or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ｃ However, C １－６ It is an alkylene group, and the C １－６ Alkylene groups consist of a halogen atom, an amino group, a hydroxyl group, and C １－４ R may be substituted with one to five identical or different substituents selected from the group consisting of alkoxy groups. ２ａ However, hydrogen atoms, halogen atoms, hydroxyl groups, C ２－３ Alkyl alkyl group, C １－４ Alkoxy group or C １－４ It is a thioalkoxy group, where AA is a group derived from D-Glu, D-Orn, D-Lys, or a compound represented by formula (AA-1) or formula (AA-2), and R １ｄ and R １ｅ However, each is independent of the hydrogen atom, C１－３ The C is an alkyl group or a polyethylene glycol group. １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－４ The substituents may be the same or different substituents selected from the group consisting of alkoxy groups, p １ is 3 or 4, p ２ A compound or a pharmaceutically acceptable salt thereof as described in item 270, wherein the ratio is 1 or 2.

[0325] [Item 287] Represented by formula (Z-3a), where m is 0 or 1, except when m is 0, (AA) ｍ C is a hydroxyl group, and Q is a phenyl group or an indolyl group, and the phenyl group and the indolyl group may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ａ However, hydrogen atoms or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３ R may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. １ｃ However, C １－３ It is an alkylene group, and the C １－３ Alkylene groups consist of a halogen atom, an amino group, a hydroxyl group, and C １－４ R may be substituted with one to three identical or different substituents selected from the group consisting of alkoxy groups. ２ａ However, hydrogen atoms, halogen atoms, C ２－３ The group is an alkyl group, a methoxy group, a methylthio group, an ethylthio group, or a tert-butylthio group, and AA is a group derived from D-Glu or a compound represented by formula (AA-2), R １ｄ and R １ｅ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, p ２ A compound or a pharmaceutically acceptable salt thereof as described in item 270, wherein the ratio is 1 or 2.

[0326] [Item 288] A compound or a pharmaceutically acceptable salt thereof, represented by any of the following formulas, as described in Item 270.

[0327] [Clause 289] A pharmaceutical composition according to any one of claims 159 to 161, comprising a plurality of antibody-drug conjugates or pharmaceutically acceptable salts thereof, wherein the average value of n is about 7.3 to 8.0.

[0328] [Clause 290] A pharmaceutical composition according to any one of claims 159 to 161, comprising a plurality of antibody-drug conjugates or pharmaceutically acceptable salts thereof, wherein the average value of n is about 7.9 to 8.0.

[0329] The antibody-drug conjugate of this disclosure, formed from a hemiastalin derivative (the drug portion), a linker, and an anti-CCR8 antibody, exhibits specific cytotoxicity against tumor-infiltrating Treg cells expressing the antigen CCR8, regardless of immune status including ADCC activity. Furthermore, it exhibits low cytotoxicity to normal cells other than CCR8-expressing cells, thus potentially becoming a highly safe anticancer agent.

[0330] This figure shows the human CCR8 expression profile of the stable human CCR8-expressing cell line #29 (Neuro2a-hCCR8#29). This figure shows the evaluation of the binding specificity of Examples ADC1 to ADC8 and Example ADC35 to Neuro2a cells, which are antigen-nonexpressing cells, in Test Example 3. This figure shows the evaluation of the antitumor effect of Test Example 4 when isotype control antibodies rIgG2b, SA214G2, or Reference Example ADC3 are administered to CT26 tumor-grafted mice. This figure shows the evaluation of the tumor microenvironment improvement effect of Test Example 5 when isotype control antibodies rIgG2b, SA214G2, or Reference Example ADC3 are administered to CT26 tumor-grafted mice. This figure shows the evaluation of the antitumor effect of Test Example 6 when isotype control antibodies rIgG2b, SA214G2, or Reference Example ADC3 are administered to K7M2 tumor-grafted mice. This figure shows the evaluation of the antitumor effect of Test Example 7 when immunodeficient mice (NOD SCID mice) transplanted with Neuro2a-hCCR8#29 tumors were administered PBS, Example ADC1, Example ADC2, Example ADC3, Example ADC4, Example ADC5, Example ADC6, or Example ADC35. This figure shows the evaluation of the antitumor effect of Test Example 8 when human CCR8 knock-in mice transplanted with MC38-Neo cells were administered PBS, 10A11, Example ADC1, or Example ADC4. This figure shows the evaluation of the tumor-infiltrating Treg cell removal ability of Test Example 9 when human CCR8 knock-in mice transplanted with MC38-Neo cells were administered PBS, 10A11, Example ADC1, or Example ADC4. This figure shows the evaluation of the antitumor effect and body weight changes in Test Example 11 when the isotype control antibody rIgG2b or reference example ADC3 was administered at each dose to CT26 tumor-grafted mice. This figure shows the evaluation of the antitumor effect and body weight changes in Test Example 12 when PBS, mCCR8GN, or reference example ADC4 was administered to LLC tumor-grafted mice. This figure shows the evaluation of the tumor microenvironment improvement effect in Test Example 13 when PBS, SA214G2, or reference example ADC3 was administered to LLC tumor-grafted mice.This figure shows the evaluation of gene changes in the tumor microenvironment of Test Example 14 when administered PBS, SA214G2, or reference example ADC3 to LLC tumor-transplanted mice. This figure shows the evaluation of gene changes in the tumor microenvironment of Test Example 14 when administered PBS, SA214G2, or reference example ADC3 to LLC tumor-transplanted mice. This figure shows the evaluation of gene changes in the tumor microenvironment of Test Example 14 when administered PBS, SA214G2, or reference example ADC3 to LLC tumor-transplanted mice. This figure shows the results of Gene Ontology analysis comparing the gene changes in the tumor microenvironment of Test Example 14 when administered PBS or SA214G2 to LLC tumor-transplanted mice. This figure shows the results of Gene Ontology analysis comparing the gene changes in the tumor microenvironment of Test Example 14 when administered PBS or reference example ADC3 to LLC tumor-transplanted mice. This figure shows the evaluation of the antitumor effect and weight changes in Test Example 15 when administered isotype control antibodies (rIgG2b and rIgG2a), anti-mPD-1 antibody + isotype control antibody (rIgG2b), reference example ADC3 + isotype control antibody (rIgG2a), or reference example ADC3 + anti-mPD-1 antibody to CT26 tumor-grafted mice. This figure shows the evaluation of the antitumor effect and weight changes in Test Example 16 when admi...

Claims

An antibody-drug conjugate represented by formula (1) or a pharmaceutically acceptable salt thereof. [In the formula, mAb represents an antibody that binds to CCR8, or a fragment of that antibody. n represents an integer from 1 to 8. L represents a group expressed by the following formulas (L-1), (L-2), (L-3), or (L-4): (In the formula, p represents an integer from 1 to 5. AB represents a peptide residue consisting of 1 to 4 amino acids selected from the group consisting of glycine (Gly), phenylalanine (Phe), valine (Val), citrulline (Cit), asparagine (Asn), alanine (Ala), glutamic acid (Glu), and aspartic acid (Asp). (The areas marked with an asterisk (*) form a bond with the nitrogen atom of the succinimide group, and the areas marked with a dashed line (*) form a bond with Z.) Z represents the base expressed by formula (Z-1), formula (Z-2), or formula (Z-3): (In the formula, m represents an integer from 0 to 4. Q represents a 6-10 member aromatic hydrocarbon ring group or a 5-10 member aromatic heterocyclic group, and the aromatic hydrocarbon ring group and the aromatic heterocyclic group may be substituted with halogen atoms, cyano groups, amino groups, or 1-3 fluorine atoms. １－３ Alkyl groups, hydroxyl groups and C １－４ It may be substituted with one to five identical or different substituents selected from the group consisting of alkoxy groups. R １ａ and R １ｂ Each of them is independently a hydrogen atom, C １－６ Alkyl alkyl group or C ３－８ Represents a saturated hydrocarbon ring group, and the alkyl group and the saturated hydrocarbon ring group are a halogen atom, a hydroxyl group, C １－３ Alkyl and C １－４ It may be substituted with one to five identical or different substituents selected from the group consisting of alkoxy groups. R １ｃ represents an alkylene group, and the C １－６ alkylene group may be substituted with the same or different 1 to 5 substituents selected from the group consisting of a halogen atom, an amino group, a hydroxy group, and a C １－６ alkoxy group, １－４ and may be substituted with the same or different 1 to 5 substituents selected from the group consisting of a halogen atom, an amino group, a hydroxy group, and a C R ２ is a hydrogen atom, a halogen atom, a hydroxyl group, C １－３ alkyl group, C １－４ Alkoxy group or C １－４ Represents a thioalkoxy group, AA represents a group derived from a glutamic acid residue (Glu), an aspartic acid residue (Asp), a lysine residue (Lys), a serine residue (Ser), an ornithine residue (Orn), or a compound represented by formula (AA-1) or formula (AA-2). (In the formula, R １ｄ and R １ｅ Each of them is independently a hydrogen atom, C １－６ Represents an alkyl group or a polyethylene glycol group, and the C １－６ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－４ It may be substituted with one to five identical or different substituents selected from the group consisting of alkoxy groups. p １ This represents an integer from 1 to 5. p ２ (represents integers from 1 to 3) When there are multiple AAs, each AA may be identical or different from the others, and the AAs are linked to each other via amide bonds in a linear or branched manner. (AA) ｍ The nitrogen atom at the N-terminus or side chain forms an amide bond with the carbonyl group (#). however, When Z is a group represented by formula (Z-1) and L is a group represented by formula (L-2), formula (L-3), or formula (L-4), m is an integer from 1 to 4, and at least one AA is a group derived from an ornithine residue or a compound represented by formula (AA-1). If Z is a base represented by formula (Z-2) or formula (Z-3) and m is 0, then (AA) ｍ (This is a hydroxyl group.) The antibody-drug conjugate according to claim 1 or a pharmaceutically acceptable salt thereof, wherein AB is a peptide residue selected from the group consisting of -Val-Cit-, -Gly-Gly-Phe-Gly-, -Ala-Ala-, -Glu-Ala-Ala-, -Gly-Asn-, -Asn-, and -Glu-Asn-. R １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－４ The antibody-drug conjugate according to claim 1, or a pharmaceutically acceptable salt thereof, which may be substituted with one to three identical or different substituents selected from the group consisting of alkoxy groups. 　 The antibody-drug conjugate according to claim 1, or a pharmaceutically acceptable salt thereof, wherein p is an integer between 2 and 5. 　 The antibody-drug conjugate according to claim 1, or a pharmaceutically acceptable salt thereof, wherein m is an integer from 0 to 2. 　 AA is a group derived from D-Glu, D-Orn, D-Lys, or a compound represented by formula (AA-1) or formula (AA-2), R １ｄ and R １ｅ Each of them is independently a hydrogen atom, C １－６ The C is an alkyl group or a polyethylene glycol group. １－６ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－４ The antibody-drug conjugate according to claim 1, or a pharmaceutically acceptable salt thereof, which may be substituted with one to three identical or different substituents selected from the group consisting of alkoxy groups. 　 Q is a phenyl group, a thienyl group, a pyridyl group, or an indolyl group, and the phenyl group, the thienyl group, the pyridyl group, and the indolyl group may be substituted with a halogen atom, a cyano group, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl groups, hydroxyl groups and C １－４ The antibody-drug conjugate according to claim 1, or a pharmaceutically acceptable salt thereof, which may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. The antibody-drug conjugate according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Z is a group represented by formula (Z-1). 　 L is a group represented by formula (L-1), formula (L-2), formula (L-3), or formula (L-4), p is an integer between 2 and 5, A and B are peptide residues composed of 1 to 4 amino acids selected from the group consisting of glycine (Gly), phenylalanine (Phe), valine (Val), citrulline (Cit), asparagine (Asn), alanine (Ala), glutamic acid (Glu), and aspartic acid (Asp). Z is a base represented by the formula (Z-1), m is 1, Q is a phenyl group, a thienyl group, a pyridyl group, or an indolyl group, and the phenyl group, the thienyl group, the pyridyl group, and the indolyl group may be substituted with a halogen atom, a cyano group, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl groups, hydroxyl groups and C １－４ They may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. R １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－４ They may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. AA is a group derived from D-Glu, D-Orn, D-Lys, or a compound represented by formula (AA-1) or formula (AA-2), R １ｄ and R １ｅ However, each is independent of the hydrogen atom, C １－３ The C is an alkyl group or a polyethylene glycol group. １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－４ They may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. p １ is 3 or 4, p ２ is 1 or 2, The antibody-drug conjugate according to claim 1 or a pharmaceutically acceptable salt thereof. 　 L is a base represented by formula (L-1) or (L-2), p is 2, Z is a base represented by the formula (Z-1), m is 1, Q is a phenyl group or an indolyl group, and the phenyl group and the indolyl group may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ They may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. R １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３ They may be substituted with one or two identical or different substituents selected from the group consisting of alkoxy groups. AA is a group derived from D-Glu, or a compound represented by formula (AA-1) or formula (AA-2), R １ｄ and R １ｅ However, each is independent of the hydrogen atom, C １－３ It is an alkyl group or polyethylene glycol group, p １ is 3 or 4, p ２ is 1 or 2, The antibody-drug conjugate according to claim 1 or a pharmaceutically acceptable salt thereof. 　 L is a base represented by formula (L-1), p is 2, Z is a base represented by the formula (Z-1), m is 1, Q is a phenyl group or an indolyl group, and the phenyl group and the indolyl group may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ It may be substituted with one substituent selected from the group consisting of alkoxy groups. R １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３ It may be substituted with one substituent selected from the group consisting of alkoxy groups. AA is D-Glu. The antibody-drug conjugate according to claim 1 or a pharmaceutically acceptable salt thereof. 　 L is a base represented by formula (L-1), p is 2, Z is a base represented by the formula (Z-1), m is 1, Q is a phenyl group, and the phenyl group may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ It may be substituted with one substituent selected from the group consisting of alkoxy groups. R １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３ It may be substituted with one substituent selected from the group consisting of alkoxy groups. AA is D-Glu. The antibody-drug conjugate according to claim 1 or a pharmaceutically acceptable salt thereof. 　 An antibody-drug conjugate according to claim 1, represented by the following formula, or a pharmaceutically acceptable salt thereof. [In the formula, n represents an integer between 1 and 8.] 　 The antibody has a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, and the heavy chain variable region and the light chain variable region are (1) Sequence IDs 27, 28, 111, and CDR-H1 consists of an amino acid sequence selected from the group consisting of amino acid sequences in which one or two amino acids are deleted, substituted, inserted and / or added in the amino acid sequence of SEQ ID NO: 27, SEQ ID NO: 28, or SEQ ID NO:

111. (2) Sequence IDs 29, 30, 31, 32, 33, 34, 35, 36, 37, and CDR-H2 consists of an amino acid sequence selected from the group consisting of amino acid sequences in which one or two amino acids are deleted, substituted, inserted and / or added in the amino acid sequence of SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36 or SEQ ID NO: 37, (3) Sequence IDs 38, 39, 40, 41, 42, 112, 113, and CDR-H3 consists of an amino acid sequence selected from the group consisting of amino acid sequences in which one or two amino acids are deleted, substituted, inserted and / or added in the amino acid sequence of SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 112 or SEQ ID NO:

113. (4) Sequence IDs 43, 55, 56, 57, and Amino acid sequences of SEQ ID NO: 43, SEQ ID NO: 55, SEQ ID NO: 56, or SEQ ID NO: 57 CDR-L1 consists of an amino acid sequence selected from the group consisting of amino acid sequences in which one or two amino acids are deleted, substituted, inserted and / or added. (5) CDR-L2 consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 44 and an amino acid sequence in which one or two amino acids are deleted, substituted, inserted and / or added in the amino acid sequence of SEQ ID NO: 44, and (6) Sequence IDs 45, 46, and CDR-L3 consists of an amino acid sequence selected from the group consisting of amino acid sequences in which one or two amino acids are deleted, substituted, inserted and / or added in the amino acid sequence of SEQ ID NO: 45 or SEQ ID NO:

46. An antibody-drug conjugate according to claim 1, or a pharmaceutically acceptable salt thereof, comprising a complementarity-determining region composed of the above. 　 The complementarity determination region is, (1) CDR-H1 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs. 27, SEQ ID NOs. 28, and SEQ ID NOs. 111, (2) CDR-H2 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 29, 30, 31, 32, 33, 34, 35, 36, and 37. (3) CDR-H3 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 38, 39, 40, 41, 42, 112, and 113. (4) (A) Sequence ID 43, (B) Sequence ID 55, (C) Sequence ID 56, (D) Sequence ID 57, (E) An amino acid sequence in which the 11th amino acid in the amino acid sequence of Sequence ID No. 43 is replaced with alanine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, arginine, asparagine, glutamine, threonine, valine, or lysine. (F) Amino acid sequences in which the 11th amino acid in the amino acid sequence of Sequence ID No. 55 is substituted with alanine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, or lysine, and (G) Amino acid sequences in which the 11th amino acid in the amino acid sequence of SEQ ID NO: 56 or SEQ ID NO: 57 is substituted with leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, arginine, or lysine. CDR-L1 consists of an amino acid sequence selected from the group comprising the following: (5) CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and (6) CDR-L3 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs. 45 and SEQ ID NOs. 46 An antibody-drug conjugate according to claim 14, or a pharmaceutically acceptable salt thereof, comprising the above. 　 The antibody-drug conjugate according to claim 15, or a pharmaceutically acceptable salt thereof, wherein CDR-H1 comprises the amino acid sequence of SEQ ID NO:

27. The antibody-drug conjugate according to claim 15, or a pharmaceutically acceptable salt thereof, wherein the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 29 or SEQ ID NO:

32. The antibody-drug conjugate according to claim 15, or a pharmaceutically acceptable salt thereof, wherein the CDR-H3 comprises SEQ ID NO: 38 or SEQ ID NO:

42. The antibody-drug conjugate according to claim 15, or a pharmaceutically acceptable salt thereof, wherein the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 43, SEQ ID NO: 55, SEQ ID NO: 56, or SEQ ID NO:

57. The complementarity determination region is, A) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 45; B) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 55, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 45; C) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 56, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 45; D) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 57, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 45; E) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 30, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 39, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; F) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 31, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; G) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 30, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; H) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; I) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 55, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; J) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 56, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; K) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 57, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; L) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; M) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 28, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 33, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; N) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 34, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; O) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 35, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; P) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 36, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; Q) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 34, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; or, R) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 37, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46, An antibody-drug conjugate according to claim 14, or a pharmaceutically acceptable salt thereof, comprising the above. 　 The complementarity determination region is, CDR-H1, consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 55, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, which consists of the amino acid sequence of Sequence ID No. 45, The antibody-drug conjugate according to claim 14 or a pharmaceutically acceptable salt thereof. 　 The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to claim 14, wherein the antibody is a humanized antibody. 　 The light chain variable region is (1) The amino acid sequences of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, or SEQ ID NO: 65 (2) Amino acid sequences in which the 34th amino acid in the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, or SEQ ID NO: 54 is substituted with alanine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, arginine, asparagine, glutamine, threonine, valine, or lysine, (3) Amino acid sequences in which the 34th amino acid in the amino acid sequence of SEQ ID NO: 58, SEQ ID NO: 61, or SEQ ID NO: 64 is substituted with alanine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, or lysine, or, (4) Amino acid sequences in which the 34th amino acid in the amino acid sequence of SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 62, or SEQ ID NO: 63 is substituted with leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, arginine, or lysine, An antibody-drug conjugate according to claim 22, or a pharmaceutically acceptable salt thereof, comprising the above. 　 The heavy chain variable region consists of an amino acid sequence having 95% or more sequence identity with the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 51, or SEQ ID NO: 52, and The light chain variable region consists of an amino acid sequence having 95% or more sequence identity with the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, or SEQ ID NO:

65. The antibody-drug conjugate according to claim 22 or a pharmaceutically acceptable salt thereof. 　 The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 51, or SEQ ID NO: 52, and The light chain variable region consists of the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, or SEQ ID NO:

129. The antibody-drug conjugate according to claim 22 or a pharmaceutically acceptable salt thereof. 　 The heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 47, and The antibody-drug conjugate according to claim 22, or a pharmaceutically acceptable salt thereof, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO:

58. The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to claim 22, wherein the antibody comprises a heavy chain constant region of human IgG1, IgG2, IgG3, or IgG4, and the heavy chain constant region may have amino acid substitutions at one to three positions selected from the group consisting of EU numbering 234, 235, 237, 297, 329, and 331. 　 The aforementioned antibody The heavy chain constant region of human IgG1 consisting of the amino acid sequence of SEQ ID NO: 66, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, or SEQ ID NO: 101, The heavy chain constant region of human IgG2 consisting of the amino acid sequence of SEQ ID NO: 91 or SEQ ID NO: 92, The heavy chain constant region of human IgG3 consisting of the amino acid sequence of SEQ ID NO: 93, and The heavy chain constant region of human IgG4 consisting of the amino acid sequence of SEQ ID NO: 94 or SEQ ID NO: 95 It includes a heavy chain constant region selected from the group consisting of the following, The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to claim 27, wherein the heavy chain constant region may have amino acid substitutions at one to three positions selected from the group consisting of EU numbering 234, 235, 237, 297, 329, and 331. 　 The heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, or SEQ ID NO:

51. The heavy chain constant region consists of the amino acid sequence of SEQ ID NO: 66, SEQ ID NO: 67, or SEQ ID NO: 68, and The antibody-drug conjugate according to claim 27 or a pharmaceutically acceptable salt thereof, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, or SEQ ID NO:

129. The aforementioned antibody A heavy chain consisting of the amino acid sequence of SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 81, SEQ ID NO: 82, or SEQ ID NO: 83, and An antibody-drug conjugate according to claim 22, or a pharmaceutically acceptable salt thereof, comprising a light chain consisting of the amino acid sequence of SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, or SEQ ID NO:

137. The antibody-drug conjugate according to claim 30, or a pharmaceutically acceptable salt thereof, wherein the antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO: 69 and a light chain consisting of the amino acid sequence of SEQ ID NO:

73. The antibody-drug conjugate according to claim 30, or a pharmaceutically acceptable salt thereof, wherein the antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO: 70 and a light chain consisting of the amino acid sequence of SEQ ID NO:

73. The antibody fragments are Fab fragment, Fab' fragment, and F(ab'). ２ The antibody-drug conjugate according to claim 1, or a pharmaceutically acceptable salt thereof, comprising a fragment, an Fv fragment, or an scFv fragment. 　 In equation (1), mAb has a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, and the heavy chain variable region and the light chain variable region are (1) CDR-H1 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs. 27 and SEQ ID NOs. 28, (2) CDR-H2 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 29, 30, 31, 32, 33, 34, 35, 36, and 37. (3) CDR-H3 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 38, 39, 40, 41 and 42, (4) (A) Sequence ID 43, (B) Sequence ID 55, (C) Sequence ID 56, (D) Sequence ID 57, (E) An amino acid sequence in which the 11th amino acid in the amino acid sequence of Sequence ID No. 43 is substituted with alanine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, arginine, or lysine. (F) Amino acid sequences in which the 11th amino acid in the amino acid sequence of Sequence ID No. 55 is substituted with alanine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, or lysine, and (G) Amino acid sequences in which the 11th amino acid in the amino acid sequence of SEQ ID NO: 56 or SEQ ID NO: 57 is substituted with leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, arginine, or lysine. CDR-L1 consists of an amino acid sequence selected from the group comprising the following: (5) CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and (6) CDR-L3 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs. 45 and SEQ ID NOs. 46 An antibody or antibody fragment containing a complementarity-determining region composed of the following: n is an integer from 1 to 8, L is a base represented by formula (L-1), p is 2, Z is a base represented by the formula (Z-1), m is 1, Q is a phenyl group, and the phenyl group may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ It may be substituted with one substituent selected from the group consisting of alkoxy groups. R １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３ It may be substituted with one substituent selected from the group consisting of alkoxy groups. AA is D-Glu. The antibody-drug conjugate according to claim 1 or a pharmaceutically acceptable salt thereof. 　 In equation (1), mAb has a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, and the heavy chain variable region and the light chain variable region are A) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 45; B) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 55, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 45; C) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 56, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 45; D) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 57, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 45; E) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 30, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 39, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; F) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 31, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; G) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 30, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; H) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; I) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 55, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; J) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 56, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; K) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 57, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; L) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; M) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 28, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 33, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; N) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 34, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; O) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 35, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; P) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 36, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; Q) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 34, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; or, R) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 37, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46 An antibody or antibody fragment containing a complementarity-determining region composed of the following: n is an integer from 1 to 8, L is a base represented by formula (L-1), p is 2, Z is a base represented by the formula (Z-1), m is 1, Q is a phenyl group, and the phenyl group may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ It may be substituted with one substituent selected from the group consisting of alkoxy groups. R １ａ and R １ｂ each independently is a hydrogen atom or a C １－３ alkyl group, and the C １－３ alkyl group may be substituted with one substituent selected from the group consisting of a halogen atom, a hydroxy group, and a C １－３ alkoxy group AA is D-Glu. The antibody-drug conjugate according to claim 1 or a pharmaceutically acceptable salt thereof. 　 In equation (1), mAb has a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 51, or SEQ ID NO: 52, and The light chain variable region is an antibody or antibody fragment consisting of the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, or SEQ ID NO:

65. n is an integer from 1 to 8, L is a base represented by formula (L-1), p is 2, Z is a base represented by the formula (Z-1), m is 1, Q is a phenyl group, and the phenyl group may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ It may be substituted with one substituent selected from the group consisting of alkoxy groups. R １ａ and R １ｂ each independently represents a hydrogen atom or a C １－３ alkyl group, and the C １－３ alkyl group may be substituted with one substituent selected from the group consisting of a halogen atom, a hydroxy group, and a C １－３ alkoxy group. AA is D-Glu. The antibody-drug conjugate according to claim 1 or a pharmaceutically acceptable salt thereof. 　 In equation (1), mAb is, A) A heavy chain consisting of the amino acid sequence of SEQ ID NO: 69, SEQ ID NO: 70, or SEQ ID NO: 71, and a light chain consisting of the amino acid sequence of SEQ ID NO: 72, SEQ ID NO: 73, or SEQ ID NO: 74, B) A heavy chain consisting of the amino acid sequence of SEQ ID NO: 75, SEQ ID NO: 76, or SEQ ID NO: 77, and a light chain consisting of the amino acid sequence of SEQ ID NO: 78, SEQ ID NO: 79, or SEQ ID NO: 80, C) A heavy chain consisting of the amino acid sequence of SEQ ID NO: 81, SEQ ID NO: 82, or SEQ ID NO: 83, and a light chain consisting of the amino acid sequence of SEQ ID NO: 84 or SEQ ID NO: 85, An antibody or antibody fragment composed of a combination of heavy and light chains selected from the group consisting of the following: n is an integer from 1 to 8, L is a base represented by formula (L-1), p is 2, Z is a base represented by the formula (Z-1), m is 1, Q is a phenyl group, and the phenyl group may be substituted with a halogen atom, an amino group, or 1 to 3 fluorine atoms. １－３ Alkyl and C １－４ It may be substituted with one substituent selected from the group consisting of alkoxy groups. R １ａ and R １ｂ However, each is independent of a hydrogen atom or C １－３ It is an alkyl group, and the C １－３ Alkyl alkyl groups consist of a halogen atom, a hydroxyl group, and C １－３ It may be substituted with one substituent selected from the group consisting of alkoxy groups. AA is D-Glu. The antibody-drug conjugate according to claim 1 or a pharmaceutically acceptable salt thereof. 　 represented by the following formula, and in the following formula, mAb has a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, and the heavy chain variable region and the light chain variable region are A) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 45; B) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 55, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 45; C) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 56, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 45; D) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 57, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 45; E) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 30, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 39, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; F) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 31, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; G) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 30, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; H) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; I) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 55, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; J) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 56, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; K) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 57, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; L) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; M) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 28, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 33, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; N) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 34, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; O) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 35, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; P) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 36, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; Q) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 34, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; or, R) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 37, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46 An antibody or antibody fragment containing a complementarity-determining region composed of the following: n is an integer from 1 to 8. The antibody-drug conjugate according to claim 1 or a pharmaceutically acceptable salt thereof. 　 It is expressed by the following formula, and in the following formula, mAb has a heavy chain variable region in the heavy chain and a light chain variable region in the light chain, The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 47, and The light chain variable region is an antibody or antibody fragment consisting of the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 58, SEQ ID NO: 59, or SEQ ID NO:

60. n is an integer from 1 to 8. The antibody-drug conjugate according to claim 1 or a pharmaceutically acceptable salt thereof. 　 It is expressed by the following formula, and in the following formula, mAb is an antibody or antibody fragment composed of a heavy chain consisting of the amino acid sequence of SEQ ID NO: 69 and a light chain consisting of the amino acid sequence of SEQ ID NO:

73. n is an integer from 1 to 8. The antibody-drug conjugate according to claim 1 or a pharmaceutically acceptable salt thereof. 　 It is expressed by the following formula, and in the following formula, mAb is an antibody or antibody fragment composed of a heavy chain consisting of the amino acid sequence of SEQ ID NO: 70 and a light chain consisting of the amino acid sequence of SEQ ID NO:

73. n is an integer from 1 to 8. The antibody-drug conjugate according to claim 1 or a pharmaceutically acceptable salt thereof. 　 The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that the antibody-drug conjugate or a pharmaceutically acceptable salt thereof binds to a CCR8 antigen present on the cell surface and is internalized into the cell. 　 A pharmaceutical composition comprising an antibody-drug conjugate according to any one of claims 1 to 42 or a pharmaceutically acceptable salt thereof. 　 A pharmaceutical composition for treating cancer, comprising an antibody-drug conjugate according to any one of claims 1 to 42 or a pharmaceutically acceptable salt thereof. 　 A pharmaceutical composition for removing CCR8-positive Treg cells, comprising an antibody-drug conjugate according to any one of claims 1 to 42 or a pharmaceutically acceptable salt thereof. 　 The pharmaceutical composition according to claim 43, comprising a plurality of the antibody-drug conjugate or a pharmaceutically acceptable salt thereof, wherein the average value of n is approximately 7.3 to 8.

0. The pharmaceutical composition according to claim 44, comprising a plurality of the antibody-drug conjugate or a pharmaceutically acceptable salt thereof, wherein the average value of n is approximately 7.3 to 8.

0. The pharmaceutical composition according to claim 45, comprising a plurality of the antibody-drug conjugate or a pharmaceutically acceptable salt thereof, wherein the average value of n is approximately 7.3 to 8.

0. An anticancer agent comprising an antibody-drug conjugate according to any one of claims 1 to 42 or a pharmaceutically acceptable salt thereof. 　 The anticancer agent according to claim 49, wherein the cancer is breast cancer, stomach cancer, cervical cancer, colorectal cancer, rectal cancer, glioma, lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, kidney cancer, skin cancer, thyroid cancer, bladder cancer, head and neck cancer, uterine cancer, lung cancer, liver cancer, colon cancer, mesothelioma, multiple myeloma, melanoma, or leukemia. 　 Use of an antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 42 for the manufacture of a cancer treatment agent. 　 A method for treating cancer, comprising administering to a patient in need of treatment an antibody-drug conjugate according to any one of claims 1 to 42 or a pharmaceutically acceptable salt thereof. 　 An antibody-drug conjugate according to any one of claims 1 to 42, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer. 　 An antibody-drug conjugate or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 42, for treating cancer in combination with one or more anticancer compounds selected from the group consisting of anticancer alkylating agents, anticancer antimetabolites, anticancer antibiotics, anticancer platinum-coordinate compounds, anticancer camptothecin derivatives, anticancer tyrosine kinase inhibitors, anticancer serine / threonine kinase inhibitors, anticancer phospholipid kinase inhibitors, anticancer monoclonal antibodies, interferons, biological response modifiers, hormones, cancer immunotherapy agents, epigenetics-related molecule inhibitors, autophagy inhibitors, angiogenesis inhibitors, and protein post-translational modification inhibitors, or a pharmaceutically acceptable salt thereof. 　 The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to claim 54, wherein the anticancer compound is a cancer immunotherapy agent. 　 The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to claim 55, wherein the cancer immunotherapy agent is an immune checkpoint inhibitor. 　 The antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to claim 56, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody. 　 An antibody-drug conjugate according to any one of claims 1 to 42 or a pharmaceutically acceptable salt thereof, A pharmaceutical composition comprising one or more anticancer agents selected from the group consisting of anticancer alkylating agents, anticancer antimetabolites, anticancer antibiotics, anticancer platinum-coordinate compounds, anticancer camptothecin derivatives, anticancer tyrosine kinase inhibitors, anticancer serine / threonine kinase inhibitors, anticancer phospholipid kinase inhibitors, anticancer monoclonal antibodies, interferons, biological response modifiers, hormones, cancer immunotherapy agents, epigenetics-related molecule inhibitors, autophagy inhibitors, angiogenesis inhibitors, and protein post-translational modification inhibitors. 　 The pharmaceutical composition according to claim 58, wherein the anticancer agent is a cancer immunotherapy agent. 　 The pharmaceutical composition according to claim 59, wherein the cancer immunotherapy agent is an immune checkpoint inhibitor. 　 The pharmaceutical composition according to claim 60, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody. 　 An antibody-drug conjugate according to any one of claims 1 to 42 or a pharmaceutically acceptable salt thereof, A kit for treating cancer comprising a drug selected from the group consisting of anticancer alkylating agents, anticancer antimetabolites, anticancer antibiotics, anticancer platinum-coordinate compounds, anticancer camptothecin derivatives, anticancer tyrosine kinase inhibitors, anticancer serine / threonine kinase inhibitors, anticancer phospholipid kinase inhibitors, anticancer monoclonal antibodies, interferons, biological response modifiers, hormones, cancer immunotherapy agents, epigenetics-related molecule inhibitors, autophagy inhibitors, angiogenesis inhibitors, and protein post-translational modification inhibitors. 　 The kit for treating cancer according to claim 62, wherein the drug is a cancer immunotherapy agent. 　 The kit for treating cancer according to claim 63, wherein the cancer immunotherapy agent is an immune checkpoint inhibitor. 　 The kit for treating cancer according to claim 64, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody. The heavy chain has a heavy chain variable region, The light chain has a variable light chain region, The heavy chain variable region and the light chain variable region are (1) Sequence IDs 27, 28, 111, and CDR-H1 consists of an amino acid sequence selected from the group consisting of amino acid sequences in which one or two amino acids are deleted, substituted, inserted and / or added in the amino acid sequence of SEQ ID NO: 27, SEQ ID NO: 28, or SEQ ID NO:

111. (2) Sequence IDs 29, 30, 31, 32, 33, 34, 35, 36, 37, and CDR-H2 consists of an amino acid sequence selected from the group consisting of amino acid sequences in which one or two amino acids are deleted, substituted, inserted and / or added in the amino acid sequence of SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36 or SEQ ID NO: 37, (3) Sequence IDs 38, 39, 40, 41, 42, 112, 113, and CDR-H3 consists of an amino acid sequence selected from the group consisting of amino acid sequences in which one or two amino acids are deleted, substituted, inserted and / or added in the amino acid sequence of SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 112 or SEQ ID NO:

113. (4) Sequence IDs 43, 55, 56, 57, and CDR-L1 consists of an amino acid sequence selected from the group consisting of amino acid sequences in which one or two amino acids are deleted, substituted, inserted and / or added in the amino acid sequence of SEQ ID NO: 43, SEQ ID NO: 55, SEQ ID NO: 56, or SEQ ID NO:

57. (5) CDR-L2 consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 44 and an amino acid sequence in which one or two amino acids are deleted, substituted, inserted and / or added in the amino acid sequence of SEQ ID NO: 44, and (6) Sequence IDs 45, 46, and CDR-L3 consists of an amino acid sequence selected from the group consisting of amino acid sequences in which one or two amino acids are deleted, substituted, inserted and / or added in the amino acid sequence of SEQ ID NO: 45 or SEQ ID NO:

46. An antibody or antibody fragment thereof that binds to CCR8, comprising a complementarity-determining region composed of the following. 　 The complementarity determination region is, (1) CDR-H1 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs. 27, SEQ ID NOs. 28, and SEQ ID NOs. 111, (2) CDR-H2 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 29, 30, 31, 32, 33, 34, 35, 36, and 37. (3) CDR-H3 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 38, 39, 40, 41, 42, 112, and 113. (4) (A) Sequence ID 43, (B) Sequence ID 55, (C) Sequence ID 56, (D) Sequence ID 57, (E) An amino acid sequence in which the 11th amino acid in the amino acid sequence of Sequence ID No. 43 is replaced with alanine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, arginine, asparagine, glutamine, threonine, valine, or lysine. (F) Amino acid sequences in which the 11th amino acid in the amino acid sequence of Sequence ID No. 55 is substituted with alanine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, or lysine, and (G) Amino acid sequences in which the 11th amino acid in the amino acid sequence of SEQ ID NO: 56 or SEQ ID NO: 57 is substituted with leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, arginine, or lysine. CDR-L1 consists of an amino acid sequence selected from the group comprising the following: (5) CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 44, and (6) CDR-L3 consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs. 45 and SEQ ID NOs. 46 The antibody or antibody fragment according to claim 66, comprising the above. 　 The antibody or antibody fragment according to claim 67, wherein CDR-H1 consists of the amino acid sequence of SEQ ID NO:

27. The antibody or antibody fragment according to claim 67, wherein the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 29 or SEQ ID NO:

32. The antibody or antibody fragment according to claim 67, wherein the CDR-H3 comprises SEQ ID NO: 38 or SEQ ID NO:

42. The antibody or antibody fragment according to claim 67, wherein the CDR-L1 comprises the amino acid sequence of SEQ ID NO: 43, SEQ ID NO: 55, SEQ ID NO: 56, or SEQ ID NO:

57. The complementarity determination region is, A) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 45; B) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 55, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 45; C) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 56, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 45; D) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 57, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 45; E) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 30, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 39, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; F) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 31, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; G) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 30, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; H) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; I) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 55, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; J) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 56, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; K) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 32, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 57, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; L) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; M) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 28, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 33, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; N) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 34, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 41, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; O) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 35, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; P) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 36, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46; Q) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 34, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 42, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 46; or, R) CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 37, CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 40, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 43, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 46, The antibody or antibody fragment according to claim 66, comprising the above. 　 The complementarity determination region is, CDR-H1, consisting of the amino acid sequence of SEQ ID NO: 27, CDR-H2, consisting of the amino acid sequence of SEQ ID NO: 29, CDR-H3, consisting of the amino acid sequence of SEQ ID NO: 38, CDR-L1, consisting of the amino acid sequence of SEQ ID NO: 55, CDR-L2, consisting of the amino acid sequence of SEQ ID NO: 44, and CDR-L3, consisting of the amino acid sequence of SEQ ID NO: 45 The antibody or antibody fragment according to claim 66, comprising the above. 　 The antibody or antibody fragment according to claim 66, wherein the antibody is a humanized antibody. 　 The light chain variable region is (1) The amino acid sequences of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, or SEQ ID NO: 65 (2) Amino acid sequences in which the 34th amino acid in the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, or SEQ ID NO: 54 is substituted with alanine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, arginine, asparagine, glutamine, threonine, valine, or lysine, (3) Amino acid sequences in which the 34th amino acid in the amino acid sequence of SEQ ID NO: 58, SEQ ID NO: 61, or SEQ ID NO: 64 is substituted with alanine, leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, or lysine, or, (4) Amino acid sequences in which the 34th amino acid in the amino acid sequence of SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 62, or SEQ ID NO: 63 is substituted with leucine, isoleucine, phenylalanine, tryptophan, tyrosine, aspartic acid, glutamic acid, arginine, or lysine, The antibody or antibody fragment according to claim 74, comprising the above. 　 The heavy chain variable region consists of an amino acid sequence having 95% or more sequence identity with the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 51, or SEQ ID NO: 52, and The antibody or antibody fragment according to claim 74, wherein the light chain variable region consists of an amino acid sequence having 95% or more sequence identity with the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, or SEQ ID NO:

65. The heavy chain variable region consists of the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 51, or SEQ ID NO: 52, and The light chain variable region consists of the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, or SEQ ID NO:

129. The antibody or antibody fragment according to claim 74. 　 The heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 47, and The antibody or antibody fragment according to claim 74, wherein the light chain variable region consists of the amino acid sequence of SEQ ID NO:

58. The antibody or antibody fragment according to claim 74, wherein the antibody comprises a heavy chain constant region of human IgG1, IgG2, IgG3, or IgG4, and the heavy chain constant region may have amino acid substitutions at one to three positions selected from the group consisting of EU numbering 234, 235, 237, 297, 329, and 331. 　 The aforementioned antibody The heavy chain constant region of human IgG1 consisting of the amino acid sequence of SEQ ID NO: 66, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, or SEQ ID NO: 101, The heavy chain constant region of human IgG2 consisting of the amino acid sequence of SEQ ID NO: 91 or SEQ ID NO: 92, The heavy chain constant region of human IgG3 consisting of the amino acid sequence of SEQ ID NO: 93, and The heavy chain constant region of human IgG4 consisting of the amino acid sequence of SEQ ID NO: 94 or SEQ ID NO: 95 It includes a heavy chain constant region selected from the group consisting of the following, The antibody or antibody fragment according to claim 79, wherein the heavy chain constant region may have amino acid substitutions at one to three positions selected from the group consisting of EU numbering positions 234, 235, 237, 297, 329, and 331. 　 The heavy chain variable region of the antibody consists of the amino acid sequence of SEQ ID NO: 47, SEQ ID NO: 48, or SEQ ID NO:

51. The heavy chain constant region consists of the amino acid sequence of SEQ ID NO: 66, SEQ ID NO: 67, or SEQ ID NO: 68, and The antibody or antibody fragment according to claim 79, wherein the light chain variable region consists of the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, or SEQ ID NO:

129. The aforementioned antibody A heavy chain consisting of the amino acid sequence of SEQ ID NO: 69, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 81, SEQ ID NO: 82, or SEQ ID NO: 83, and The antibody or antibody fragment according to claim 74, comprising a light chain consisting of the amino acid sequence of SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, or SEQ ID NO:

137. The antibody or antibody fragment according to claim 82, wherein the antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO: 69 and a light chain consisting of the amino acid sequence of SEQ ID NO:

73. The antibody or antibody fragment according to claim 82, wherein the antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO: 70 and a light chain consisting of the amino acid sequence of SEQ ID NO:

73. The antibody fragments are Fab fragment, Fab' fragment, and F(ab'). ２ The antibody or antibody fragment according to claim 66, which is a fragment, an Fv fragment, or an scFv fragment. 　 Use of an antibody or antibody fragment according to any one of claims 66 to 85 for the manufacture of a cancer treatment agent.

Images